Anti-CTLA4 / Anti-PD-1 Bispecific Antibody and Its Uses

By modifying the Fc fragment and optimizing variable domains of anti-CTLA4/anti-PD-1 bispecific antibodies to reduce receptor binding, the antibodies minimize immune cell damage and enhance tumor treatment efficacy.

KR103046700B1Active Publication Date: 2026-11-11AKESO BIOPHARMA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020227006972
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-02
Filing Date
2020-07-31
Publication Date
2026-11-11
Estimated Expiration
2040-07-31

AI Technical Summary

Technical Problem

Current anti-CTLA4/anti-PD-1 bispecific antibodies cause significant ADCC, ADCP, and/or CDC activity on immune cells, leading to potential damage and limiting their therapeutic efficacy in tumor treatment.

Method used

Modifying the Fc fragment of the anti-CTLA4/anti-PD-1 antibody to reduce its binding affinity to Fc receptors, specifically through mutations at positions 234, 235, and 237 of the heavy chain constant, and optimizing the variable domains of the immunoglobulin and single-chain antibody regions to enhance specificity and reduce immune cell damage.

Benefits of technology

The modified bispecific antibodies exhibit reduced ADCC, ADCP, and CDC activity on immune cells while maintaining or enhancing therapeutic efficacy against tumors by targeting CTLA4 and PD-1 pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112022022638166-PCT00044_ABST
    Figure 112022022638166-PCT00044_ABST
Patent Text Reader

Abstract

The present invention relates to the field of tumor treatment and molecular immunology, and in particular to an anti-CTLA4 / anti-PD-1 bispecific antibody and its uses. Specifically, the anti-CTLA4 / anti-PD-1 bispecific antibody comprises a first protein-active region targeting PD-1 and a second protein-active region targeting CTLA4, wherein, according to the EU numbering system, the heavy chain constant of the immunoglobulin contained within the bispecific antibody possesses mutations at any two or three of positions 234, 235, and 237, and the affinity constant of the bispecific antibody for FcγRIIIa and / or C1q is reduced after the mutation compared to the affinity constant prior to the mutation. The bispecific antibody of the present invention can specifically bind well to CTLA4 and PD-1, can specifically alleviate the immunosuppression of CTLA4 and PD-1 in an organism, and can activate T lymphocytes, thereby possessing good applicability.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to the field of tumor treatment and molecular immunology, and in particular to anti-CTLA4 / anti-PD-1 bispecific antibodies and their uses. More specifically, the present invention relates to mutant anti-CTLA4 / anti-PD-1 bispecific antibodies. Background Technology

[0002] The transmembrane receptor PD-1 (programmed cell death protein 1) is a member of the CD28 family and is expressed in activated T cells, B cells, and myeloid cells. Both ligands of PD-1, namely PDL1 (programmed cell death 1 ligand 1, or PDL-1) and PDL2 (programmed cell death 1 ligand 2, or PDL-2), are members of the B7 superfamily. PDL1 is widely expressed in various cells, including T cells, B cells, endothelial cells, and epithelial cells, while PDL2 is expressed only in antigen-presenting cells, e.g., dendritic cells and macrophages.

[0003] The PD-1 / PDL1 signaling pathway plays a crucial role in immune tolerance, microbial infection, and tumor immune escape. PD-1 is primarily expressed in immune cells, such as T cells, while its ligand, PDL1, is highly expressed in multiple human tumor tissues. Blocking the PD-1 / PDL1 signaling pathway can activate suppressed T cells, which then attack cancer cells. Blocking the PD-1 / PDL1 signaling pathway can promote the proliferation of tumor antigen-specific T cells, activate the process of tumor cell death, and also inhibit local tumor growth (Julie R et al., 2012). N Engl J Med ., 366: 2455-2465). Additionally, tumors with high PDL1 expression are associated with hard-to-detect cancers (Hamanishi et al., 2007, Proc. Natl. Acad. Sci. USAAn effective method is to administer anti-PD-1 antibodies to modulate PD-1 expression. Due to the broad antitumor potential and remarkable efficacy of PD-1 antibodies, antibodies that generally target the PD-1 pathway are used in various tumors, e.g., non-small cell lung cancer, renal cell carcinoma, ovarian cancer, and melanoma (Homet MB, Parisi G., et al., 2015, Semin Oncol ., 42(3): 466-473), leukemia and anemia (Held SA, Heine A, et al., 2013, Curr Cancer Drug Targets It will cause a breakthrough in the treatment of ., 13(7): 768-74).

[0004] Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and CD28 molecules are very similar in terms of gene structure, chromosomal location, sequence homology, and gene expression. Both molecules are receptors for the co-stimulatory molecule B7 and are primarily expressed on the surface of activated T cells. The binding of CTLA4 to B7 inhibits the activation of mouse and human T cells and plays a negative regulatory role in T cell activation.

[0005] CTLA4 antibodies (or anti-CTLA4 monoclonal antibodies) or CTLA4 ligands can block the transmission of negative regulatory signals by CTLA4 to T cells by interfering with CTLA4 binding to its natural ligand, and can enhance the responsiveness of T cells to various antigens. In this regard, in vivo and in vitro studies are essentially consistent. Currently, CTLA4 monoclonal antibodies are in clinical trials or have been approved for the treatment of prostate cancer, bladder cancer, colorectal cancer, gastric cancer, liver cancer, malignant melanoma, etc. (Grosso JF., Jure-Kunkel MN., 2013, Cancer Immun. , 13: 5).

[0006] Interleukin 2 (IL-2) is produced by T cells. It is a growth factor that regulates T cell subgroups and is a key factor in regulating immune responses. It promotes the proliferation of activated B cells and participates in antibody responses, hematopoiesis, and tumor surveillance. Recombinant human IL-2 has been approved by the U.S. FDA for the treatment of toxic tumors, including melanoma and renal tumors, while clinical studies are currently underway to treat chronic viral infections (Chavez, AR, et al., 2009, Ann. NY Acad. Sci. , 1182: p.14-27). CTLA4 and CTLA4 antibodies are important influencing factors of T cell function and disrupt the immune microenvironment within the body. In vitro and in vivo studies have demonstrated that CTLA4 antibodies can specifically alleviate the immunosuppression of CTLA4, activate T cells, induce IL-2 production, and show promise for broad applications in gene therapy for diseases such as tumors and parasitic infections.

[0007] CTLA4 antibodies can exhibit specific therapeutic effects and significant efficacy against diseases, and can be used to supplement traditional drugs and to analyze gene therapy, a new means.

[0008] Bispecific antibodies, also known as diactive antibodies, are specific drugs that target two different antigens simultaneously and can be produced by immuno-autoclaving. Alternatively, they can be obtained by genetic engineering. Genetic engineering offers flexibility in terms of binding site optimization, synthetic forms, and yield, and thus possesses specific advantages. Currently, more than 45 forms have been demonstrated (Dafne Muller, Kontermann R E., 2010, BioDrugs , 24(2): 89-98). A number of developed bispecific antibodies are IgG-scFv, i.e., Morrison format (Coloma MJ, Morrison SL., 1997, Nat Biotechnol.( , 15: 159-163), and this has been proven to be one of the ideal forms of bispecific antibodies due to its similarity to the naturally occurring IgG form and its advantages in antibody engineering, expression, and purification (Miller BR, Demarest SJ, et al., 2010, Protein Eng Des Sel , 23: 549-57; Fitzgerald J, Lugovskoy A., 2011; MAbs , 3: 299-309).

[0009] ADCC (antibody-dependent cell-mediated cytotoxicity) refers to the death of target cells by killer cells (NK cells, macrophages, etc.) mediated by the binding of the Fab fragment of an antibody to an epitope of a virus-infected cell or tumor cell and the binding of the Fc fragment of an antibody to an Fc receptor (FcR) on the surface of the killer cell.

[0010] Complement-dependent cytotoxicity (CDC) refers to the specific binding of antibodies to corresponding antigens on the cell membrane surface, forming a complex that activates the complement system. This further leads to the formation of MACs on the surface of target cells, subsequently resulting in the lysis of the target cells. Complement can induce the lysis of various bacteria and other pathogenic organisms and is an important defense mechanism against infection by pathogenic organisms.

[0011] Fc receptors belong to the immunoglobulin family, which are expressed on the surface of specific immune cells to recognize the antibody Fc region and mediate an immune response. After the Fab region recognizes an antigen, the antibody's Fc region binds to the Fc receptor on the immune cell (e.g., killer cell) to initiate phagocytosis and the immune cell's response actions, such as ADCC.

[0012] Depending on the type of antibody recognized by the Fc receptor and the type of expressing cell, Fc receptors are primarily classified into three types: FcγR, FcαR, and FcεR. FcγR can be further classified into four subtypes: FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and FcRn (neo-Fc receptor). Among these, FcγRI, FcγRII, and FcγRIII are closely associated with ADCC effects. FcγRIII is the most dominant molecule mediating ADCC and possesses two highly homologous subtypes, FcγRIIIa and FcγRIIIb, in different cell types. In the FcγRIIIa cluster, there exist two subtypes distinguished by the site of a single nucleotide polymorphism (SNP): FcγRIIIa_V158, which possesses high affinity, and FcγRIIIa_F158, which possesses low affinity. FcγRI possesses a higher affinity for the Fc region of IgG and participates in the ADCC process; FcγRII includes three subtypes, namely FcγRIIa, FcγRIIb, and FcγRIIc (also referred to as CD32a, CD32b, and CD32c, respectively), among which FcγRIIa possesses ADCC activity; in the case of FcγRIIa, two subtypes, namely FcγRIIa_H131 and FcγRIIa_R131, exist in humans due to single nucleotide mutations; FcγRIIb is an inhibitory receptor and a typical inhibitory FcγR that inhibits the nearby ITAM pathway. For example, after the binding of an immune complex to a BCR, the Fc fragment binds to FcγRIIb on the same cell, negatively regulating B cell activation and reducing the secretion of antibodies and cytokines (Hogarth PM, Pietersz GA., 2012). NATURE REVIEWS DRUG DISCOVERY , 11(4): 311-331).

[0013] The IgG family comprises four members: IgG1, IgG2, IgG3, and IgG4. These differ in amino acid sequences within the crystallizable fragment (Fc) region of the heavy chain constant, which consequently alters their affinities for FcγR. IgG1 is the most abundant subtype in humans and is also the most common subtype used in monoclonal antibody drugs. IgG1 can bind to various FcγRs and induce ADCC and CDC effects. IgG2 possesses the lowest affinity for FcγR but can still induce monocyte-mediated ADCC by binding to FcγRIIa. IgG3 is characterized by the highest binding ability to FcγR and can induce ADCC and CDC effects greater than those of IgG1. IgG4 molecules exhibit weak binding to FcγRs other than FcγRIIa and possess a lower potential to induce CDC and NK cell-mediated ADCC. However, IgG4 subtype antibodies can mediate ADCP effects through binding to FcγRI, and ADCP effects present in antibody therapies targeting immune cells can cause damage to immune cells and lead to pharmacological side effects. Currently, there is still a need for the development of novel anti-CTLA4 / anti-PD-1 bispecific antibodies to reduce or eliminate damage caused by antibody-mediated ADCC, ADCP, and / or CDC activity on immune cells to which the anti-CTLA4 / anti-PD-1 bispecific antibody binds, and to improve the efficacy of antibody therapies.

[0014] Chemotherapy is currently mainly classified into the following nine classes (He Jie, et al., Clinical Oncology, Beijing, People's Medical Publishing House, 2016: 230-237). The first class consists of drugs that bind directly to DNA and interfere with DNA replication, including various alkylating agents, mitomycin, bleomycin, dacarbazine, lead-based drugs (e.g., cisplatin and carboplatin), camptothecin, and derivatives thereof. The second class consists of drugs intended to prevent nucleic acid biosynthesis, which are drugs intended to inhibit the formation of DNA and RNA by primarily affecting the enzyme systems of tumor cells and blocking the synthesis of DNA and RNA precursors, including methotrexate, fluorouracil, 6-mercaptopurine, hydroxyurea, and cytarabine; such drugs act primarily on cells in the S phase and are antimetabolite chemotherapy drugs and cell cycle-specific anticancer agents. The third class consists of chemotherapy drugs that affect transcription through pharmacological mechanisms in which the drug is inserted into the DNA double helix and forms non-covalent bonds with the DNA double helix, thereby interfering with the transcription of genetic information on DNA into DNA-dependent mRNA and causing compromised template function and disrupted transcription. The fourth class consists of those that affect tubulin and mitosis, including vinca alkaloids, podophyllotoxins, and taxanes. The fifth class consists of drugs that block microbial protein synthesis and affect ribosome function; a representative example of such a drug is haringtonin, which inhibits the initiation of protein synthesis, degrades ribosomes, and releases new peptide chains, but does not block the binding of mRNA and tRNA to ribosomes; such drugs induce a reduction of nuclear DNA and cytoplasmic RNA and the depolymerization of polysomes, and inhibit mitosis.The sixth class consists of drugs that affect tumor cell membranes, such as concanavalin (ConA) and phytohemaggluticin (PHA); by binding to glycoprotein receptors on the cell membrane, they can influence DNA synthesis within tumor cells and prevent tumor cells from dividing. The seventh class consists of drugs that induce apoptosis, such as arsenic trioxide. The eighth class consists of hormones that treat tumors by regulating the endocrine system, including estrogens, anti-estrogens, progestogens, androgens, anti-androgens, corticosteroids, and anticorticosteroids (including dichlorodiphenyldichloroethane and aminoglutechimide). The ninth class consists of targeted anticancer therapies, including monoclonal antibodies, epidermal growth factor signaling inhibitors (e.g., drugs targeted against the receptor tyrosine kinase pathway), ubiquitin-proteasome inhibitors, and angiogenesis inhibitors.

[0015] Anlotinib is a quinoline derivative tyrosine kinase inhibitor. As a multi-target tyrosine kinase inhibitor (TKI), it affects tumor angiogenesis and proliferation signaling. Key targets include receptor tyrosine kinases: vascular endothelial growth factor receptor (VEGFR) 1 to 3, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) 1 to 4, platelet-derived growth factor receptor (PDGER) α and β, and stem cell factor receptor (SCFR) 7, 8, and 9. Phase 2 clinical trials indicated that anlotinib improved progression-free survival with potential benefits for overall survival (Han B, et al., Br J Cancer, 2018; 118(5): 654-661). A multicenter, double-blind, randomized Phase 3 clinical trial demonstrated extended overall progression-free survival in Chinese patients. These findings suggest that anlotinib is a well-tolerated, potential three-line or add-on treatment for patients with advanced NSCLC (Han B, et al., JAMA Oncol. , 2018 Nov.; 4(11):1569-1575).

[0016] Example 24 of International Publication No. WO2008112407 is a quinoline-derived tyrosine kinase inhibitor 1-[[[4-(4-fluoro-2-methyl-1 H Indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine and a method for preparing the same are disclosed. The structural formula of the quinoline-derived tyrosine kinase inhibitor is shown in Formula I. Anlotinib hydrochloride is a hydrochloride salt of the compound of Formula I.

[0017]

[0018] Lenvatinib, an oral multi-tyrosine kinase inhibitor developed by Eisai (Japan), is a multi-target receptor tyrosine kinase inhibitor that inhibits the kinase activity of VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). In addition to normal cell function, lenvatinib also inhibits other receptor tyrosine kinases associated with tumor growth and cancer progression, including pathogenic angiogenesis, fibroblast growth factor (FGF) receptors FGFR1, FGFR2, FGFR3, and FGFR4, "rearranged during transfection" (RET) receptor, KIT, and platelet-derived growth factor receptor α (PDGFRα). Lenvatinib also exhibits antiproliferative activity in hepatocellular carcinoma cell lines, which depends on the simultaneous inhibition of activated FGFR signaling and the phosphorylation of FGF receptor substrate 2α (FRS2α).

[0019] The structure of lenvatinib, 4-(3-chloro-4(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, is disclosed in Example 368 of U.S. Patent No. 7,612,208. U.S. Patent No. 7,253,286 discloses a mesylate salt form of lenvatinib (i.e., lenvatinib mesylate), namely 4-(3-chloro-4(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide mesylate, the chemical structure of which is provided below (Chemical Formula II):

[0020]

[0021] However, for various tumors, the disease remains uncontrollable for a long time after chemotherapy, and the 5-year survival rate remains very low. Therefore, drugs or combination therapies with lower toxicity and higher efficacy are of great significance.

[0022] Through intensive research and creative efforts, the inventors reduced ADCC, ADCP, and / or CDC against immune cells and increased the efficacy of the anti-CTLA4 / anti-PD-1 antibody by correspondingly modifying the Fc fragment of the anti-CTLA4 / anti-PD-1 antibody structure to reduce the binding ability of the Fc region to the Fc receptor.

[0023] The present invention is described in detail below.

[0024] One aspect of the present invention is

[0025] A first protein activity region targeting PD-1, and

[0026] Second protein activity domain targeting CTLA4

[0027] This relates to a bispecific antibody containing,

[0028] In this case, the first protein-active domain is an immunoglobulin and the second protein-active domain is a single-chain antibody; or, the first protein-active domain is a single-chain antibody and the second protein-active domain is an immunoglobulin;

[0029] At this time,

[0030] In the case of immunoglobulin, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 27-29, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 30-32; in the case of single-chain antibody, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 33-35, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 36-38, or;

[0031] Or, in the case of immunoglobulin, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ NOs 33-35, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ NOs 36-38; in the case of single-chain antibody, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ NOs 27-29, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences of SEQ NOs 30-32;

[0032] The immunoglobulin is a human IgG1 subtype immunoglobulin;

[0033] According to the EU numbering system, the heavy chain constant of the immunoglobulin has mutations at any two or three of positions 234, 235 and 237, and the affinity constant of the bispecific antibody for FcγRIIIa and / or C1q is reduced after the mutation compared to the affinity constant prior to the mutation; preferably, the affinity constant is measured by the Fortebio Octet system.

[0034] In one or more embodiments of the present invention, in the case of a bispecific antibody, after the mutation described above, the affinity constant of the bispecific antibody for FcγRIIIa, FcγRI, FcγRIIa_H131, FcγRIIIa_V158 and / or FcγRIIb is reduced compared to the affinity constant prior to the mutation; preferably, the affinity constant is measured by a fortebio octet system.

[0035] In one or more embodiments of the present invention, in the case of a bispecific antibody, the heavy chain constant of the immunoglobulin according to the EU numbering system has the following mutations at positions 234, 235 and / or 237:

[0036] L234A and L235A;

[0037] L234A and G237A;

[0038] L235A and G237A;

[0039] or

[0040] L234A, L235A and G237A.

[0041] In the present invention, unless otherwise specified, the character before the position number indicates the amino acid before the mutation, and the character after the position number indicates the amino acid after the mutation.

[0042] The present invention further

[0043] A first protein activity region targeting PD-1, and

[0044] Second protein activity domain targeting CTLA4

[0045] This relates to a bispecific antibody containing,

[0046] At this time

[0047] The first protein-active domain is an immunoglobulin and the second protein-active domain is a single-chain antibody; or, the first protein-active domain is a single-chain antibody and the second protein-active domain is an immunoglobulin;

[0048] At this time,

[0049] The first protein-active domain is an immunoglobulin and the second protein-active domain is a single-chain antibody; or, the first protein-active domain is a single-chain antibody and the second protein-active domain is an immunoglobulin;

[0050] In the case of immunoglobulin, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 27-29, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 30-32; in the case of single-chain antibody, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 33-35, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 36-38, or;

[0051] or,

[0052] In the case of immunoglobulin, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 33-35, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 36-38; in the case of single-chain antibody, the heavy chain variable portion comprises HCDR1-HCDR3 having the amino acid sequences described in SEQ ID NOs 27-29, and the light chain variable portion comprises LCDR1-LCDR3 having the amino acid sequences described in SEQ ID NOs 30-32;

[0053] The immunoglobulin is a human IgG1 subtype immunoglobulin;

[0054] In this case, according to the EU numbering system, the heavy chain constant of the immunoglobulin possesses the following mutations at positions 234, 235, and / or 237:

[0055] L234A and L235A;

[0056] L234A and G237A;

[0057] L235A and G237A; or

[0058] L234A, L235A and G237A.

[0059] In one or more embodiments of the present invention, in the case of a bispecific antibody, the heavy chain invariant of the immunoglobulin according to the EU numbering system

[0060] N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R, C226S, C229S, E233P, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, G236R, G236A, L328R, A330S, P331S, H268A, E318A, and K320A

[0061] Possesses one or more mutations selected from.

[0062] In one or more embodiments of the present invention, the bispecific antibody is in the form of IgG-scFv, i.e., Morrison format.

[0063] In one or more embodiments of the present invention, in the case of a bispecific antibody,

[0064] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is selected from SEQ NO. 14 and SEQ NO. 18; the amino acid sequence of the light chain variable portion of the immunoglobulin is selected from SEQ NO. 16 and SEQ NO. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is selected from SEQ NO. 2, SEQ NO. 6, SEQ NO. 10, SEQ NO. 41 and SEQ NO. 43; and the amino acid sequence of the light chain variable portion of the single-chain antibody is selected from SEQ NO. 4, SEQ NO. 8, SEQ NO. 12, SEQ NO. 42 and SEQ NO. 44, or;

[0065] or,

[0066] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is selected from SEQ NO. 2, SEQ NO. 6, SEQ NO. 10, SEQ NO. 41, and SEQ NO. 43; the amino acid sequence of the light chain variable portion of the immunoglobulin is selected from SEQ NO. 4, SEQ NO. 8, SEQ NO. 12, SEQ NO. 42, and SEQ NO. 44; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is selected from SEQ NO. 14 and SEQ NO. 18; and the amino acid sequence of the light chain variable portion of the single-chain antibody is selected from SEQ NO. 16 and SEQ NO. 20.

[0067] In one or more embodiments of the present invention, the bispecific antibody is selected from any one of the following (1)-(20):

[0068] (1)

[0069] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 16; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 2, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 4;

[0070] (2)

[0071] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 16; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 6, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 8;

[0072] (3)

[0073] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 16; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 10, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 12;

[0074] (4)

[0075] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 2, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 4;

[0076] (5)

[0077] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 6, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 8;

[0078] (6)

[0079] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 10, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 12;

[0080] (7)

[0081] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 2, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 4; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 16;

[0082] (8)

[0083] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 2, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 4; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 20;

[0084] (9)

[0085] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 6, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 8; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 16;

[0086] (10)

[0087] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 6, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 8; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 20;

[0088] (11)

[0089] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 10, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 12; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 16;

[0090] (12)

[0091] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 10, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 12; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 20;

[0092] (13)

[0093] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 16; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 41, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 42;

[0094] (14)

[0095] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 16; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 43, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 44;

[0096] (15)

[0097] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 41, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 42;

[0098] (16)

[0099] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 20; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 43, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 44;

[0100] (17)

[0101] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 41, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 42; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 16;

[0102] (18)

[0103] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 43, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 44; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 14, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 16;

[0104] (19)

[0105] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 41, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 42; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 20;

[0106] and,

[0107] (20)

[0108] The amino acid sequence of the heavy chain variable portion of the immunoglobulin is described in SEQ No. 43, and the amino acid sequence of the light chain variable portion of the immunoglobulin is described in SEQ No. 44; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 18, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 20.

[0109] In one or more embodiments of the present invention, for a bispecific antibody, the amino acid sequence of the heavy chain of the immunoglobulin is described in SEQ ID NO. 40, and the amino acid sequence of the light chain of the immunoglobulin is described in SEQ ID NO. 24.

[0110] In one or more embodiments of the present invention, in the case of a bispecific antibody, the immunoglobulin or its antigen-binding fragment is about 10 -7 Exceeding M, for example, about 10 -6 M, 10 -5 M, 10 -4 M, or 10 -3 Binding to FcγRIIIa_F158, FcγRI, FcγRIIa_H131, FcγRIIIa_V158 and / or FcγRIIb with an affinity constant greater than or greater than M; preferably, the affinity constant is measured by a fortebioctet system;

[0111] Preferably, the immunoglobulin or its antigen-binding fragment does not have a binding signal for FcγRIIIa_F158, FcγRI, FcγRIIa_H131, FcγRIIIa_V158 and / or FcγRIIb, or has a binding signal of less than 0.1 nm; preferably, the binding signal refers to a reaction value measured by the ForteBio Octet system.

[0112] In one or more embodiments of the present invention, in the case of a bispecific antibody, the immunoglobulin or its antigen-binding fragment is about 10 -9 M, for example, about 10 -8 M, 10 -7 M, 10 -6 M, or 10 -5 Binding to C1q with an affinity constant greater than or greater than M; preferably, the affinity constant is measured by a forteobio-octet system;

[0113] Preferably, the immunoglobulin or its antigen-binding fragment does not have a binding signal for C1q or has a binding signal of less than 0.1 nm; preferably, the binding signal refers to a reaction value measured by the ForteBio Octet system.

[0114] In one or more embodiments of the present invention, in the case of a bispecific antibody, a first protein functional region is connected to a second protein functional region directly or by a linker fragment and / or; a heavy chain variable of a single-chain antibody is connected to a light chain variable of a single-chain antibody directly or by a linker fragment.

[0115] In one or more embodiments of the present invention, in the case of a bispecific antibody, the linker fragment is (GGGGS) n and, n is a positive integer; preferably, n is 1, 2, 3, 4, 5 or 6.

[0116] In one or more embodiments of the present invention, in the case of a bispecific antibody, the number of the first protein-active region and the second protein-active region is independently 1, 2, or more than that.

[0117] In one or more embodiments of the present invention, in the case of a bispecific antibody, the number of first protein functional regions is 1, and the number of second protein functional regions is 2.

[0118] In one or more embodiments of the present invention, in the case of a bispecific antibody, a single-chain antibody is linked to the C-terminus of the heavy chain of the immunoglobulin. Since the immunoglobulin has two heavy chains, two single-chain antibody molecules are linked to one immunoglobulin molecule. Preferably, the two single-chain antibody molecules are identical. Preferably, the single-chain antibody is linked to the C-terminus of the heavy chain of the immunoglobulin by forming an amide bond by the aforementioned linker fragment.

[0119] In one or more embodiments of the present invention, the immutable portion of the immunoglobulin is humanized. For example, the heavy chain immutable portion is the Ig gamma-1 chain C region, accession number: P01857, and the light chain immutable portion is the Ig kappa chain C region, accession number: P01834.

[0120] In one or more embodiments of the present invention, the bispecific antibody is about 10 -5 Less than M, for example, about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Less than M or less than K D It binds to CTLA4 protein and / or PD-1 protein.

[0121] In one or more embodiments of the present invention, the bispecific antibody is a monoclonal antibody.

[0122] In one or more embodiments of the present invention, the bispecific antibody is a humanized antibody.

[0123] In one or more embodiments of the present invention, the bispecific antibody is

[0124] A first protein activity region targeting PD-1, and

[0125] Second protein activity domain targeting CTLA4

[0126] Including;

[0127] The number of the first protein functional regions is 1, and the number of the second protein functional regions is 2;

[0128] At this time, the first protein-active domain is an immunoglobulin, and the second protein-active domain is a single-chain antibody;

[0129] The amino acid sequence of the heavy chain of the immunoglobulin is described in SEQ No. 40, and the amino acid sequence of the light chain of the immunoglobulin is described in SEQ No. 24;

[0130] The amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ ID No. 43, and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ ID No. 44;

[0131] Single-chain antibodies are attached to the C-terminus of the heavy chain of immunoglobulin;

[0132] A first protein functional region is connected to a second protein functional region by a first linker fragment; and a heavy chain variable portion of a single-chain antibody is connected to a light chain variable portion of a single-chain antibody by a second linker fragment; the first linker fragment and the second linker fragment are identical or different;

[0133] Preferably, the amino acid sequences of the first linker fragment and the second linker fragment are independently selected from SEQ ID NO. 25 and SEQ ID NO. 26;

[0134] Preferably, the amino acid sequences of the first linker fragment and the second linker fragment are described in Sequence No. 26.

[0135] Another aspect of the present invention relates to an isolated nucleic acid molecule encoding a bispecific antibody according to any embodiment of the present invention.

[0136] The present invention also relates to a vector comprising an isolated nucleic acid molecule of the present invention.

[0137] The present invention also relates to a host cell comprising the isolated nucleic acid molecule of the present invention or the vector of the present invention.

[0138] Another aspect of the present invention relates to a conjugate comprising an antibody or an antigen-binding fragment thereof and a conjugated moiety, wherein the immunoglobulin is a bispecific antibody according to any embodiment of the present invention and the conjugated moiety is a detectable label; preferably, the conjugated moiety is a radioisotope, a fluorescent substance, a luminescent substance, a coloring substance, or an enzyme.

[0139] Another aspect of the present invention relates to a kit comprising a bispecific antibody according to any embodiment of the present invention or comprising a conjugate of the present invention;

[0140] Preferably, the kit further comprises a second antibody capable of specifically recognizing an immunoglobulin or an antigen-binding fragment thereof; optionally, the second antibody further comprises a detectable label, e.g., a radioisotope, a fluorescent substance, a luminescent substance, a coloring substance, or an enzyme.

[0141] Another aspect of the present invention relates to the use of a bispecific antibody or conjugate according to any embodiment of the present invention in the manufacture of a kit for detecting the presence or level of PD-1 and / or CTLA4 in a sample.

[0142] Another aspect of the present invention relates to a pharmaceutical composition comprising a bispecific antibody or conjugate according to any embodiment of the present invention; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0143] In one or more embodiments of the present invention, the pharmaceutical composition further comprises one or more anti-tumor chemotherapy agents;

[0144] Preferably, the anti-tumor chemotherapy agent is a tyrosine kinase inhibitor; more preferably, the anti-tumor chemotherapy agent is anlotinib or a pharmaceutically acceptable salt thereof (e.g., hydrochloride salt), or lenvatinib or a pharmaceutically acceptable salt thereof (e.g., mesylate salt).

[0145] In one or more embodiments of the present invention, the unit dose of the pharmaceutical composition is 100-1000 mg, 200-800 mg, 200-500 mg, 300-600 mg, 400-500 mg, or 450 mg based on the mass of the bispecific antibody.

[0146] Another aspect of the present invention relates to a combination product comprising a first product and a second product in separate packages,

[0147] At this time,

[0148] The first product comprises a bispecific antibody, conjugate, or pharmaceutical composition according to any embodiment of the present invention;

[0149] The second product comprises one or more anti-tumor chemotherapy agents; preferably, the anti-tumor chemotherapy agent is a tyrosine kinase inhibitor; more preferably, the anti-tumor chemotherapy agent is anlotinib or a pharmaceutically acceptable salt thereof (e.g., hydrochloride salt), or lenvatinib or a pharmaceutically acceptable salt thereof (e.g., mesylate salt);

[0150] Preferably, the first product and the second product independently further comprise one or more pharmaceutically acceptable excipients;

[0151] Preferably, the combination product further includes a package insert.

[0152] In one or more embodiments of the present invention, for a combination product, the unit dose of the first product is 100-1000 mg, 200-800 mg, 200-500 mg, 300-600 mg, 400-500 mg, or 450 mg based on the mass of the bispecific antibody.

[0153] In one or more embodiments of the present invention, for a combination product, the unit dose of the second product is 0.1-100 mg, 0.5-50 mg, 1-20 mg, 2-15 mg, 4-12 mg, or 8-12 mg based on the mass of the active ingredient.

[0154] In one or more embodiments of the present invention, for a combination product, the unit dose of the second product is 1-20 mg, 2-15 mg, 4-12 mg, or 8-12 mg based on the mass of the active ingredient.

[0155] Another aspect of the present invention relates to the use of a bispecific antibody, conjugate, pharmaceutical composition, or combination product according to any embodiment of the present invention in the manufacture of a drug for treating and / or preventing a tumor or anemia, or in the manufacture of a drug for diagnosing a tumor or anemia; preferably, the tumor is selected from one or more of melanoma, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, leukemia, breast cancer, mesothelioma, cervical cancer, endometrial cancer, lymphoma, and nasopharyngeal cancer;

[0156] Preferably, the tumor is a solid tumor of the MSI-H / dMMR phenotype; preferably, the tumor is colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm of the MSI-H / dMMR phenotype;

[0157] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer, and squamous cell lung cancer;

[0158] Preferably, the gastric cancer is a gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma.

[0159] MSI stands for microsatellite instability. Microsatellites are short serial repeats throughout the human genome, containing 10 to 50 repeats of one, two, or more nucleotides. In certain abnormal cells, such as tumors, microsatellites are altered in length by the insertion or deletion of repeat units compared to normal cells. Such alterations are referred to as MSI. Based on instability and degree, MSI can be classified into high microsatellite instability (MSI-H), low microsatellite instability (MSI-L), and microsatellite stability (MSS). The primary cause of MSI is DNA mismatch repair (MMR). Human mismatch repair genes (MMR genes) can express corresponding mismatch repair proteins through transcription and translation. The absence of any MMR protein can lead to a deficiency in mismatch repair, and base pair mismatches will accumulate during DNA replication due to such deficiency, consequently causing MSI. Approximately 15% of colorectal cancers are caused by the MSI pathway. This was first reported in colorectal cancer and can also occur in gastric cancer, endometrial cancer, and adrenocortical carcinoma (Baretti M et al., Pharmacol Ther. , 2018; 189: 45-62). In addition, MSI-H / dMMR characteristics were also confirmed in subsequent studies in mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm.

[0160] MSI-H and dMMR represent the results of two different assays that are biologically consistent and are referred to as MSI-H / dMMR or MSI-high / dMMR, while MSI-L and MSS are phenotypes of proficient MMR (pMMR). Detection of dMMR involves performing immunohistochemistry of protein expression for four mismatch genes—MSH2, MLH1, MSH6, and PMS2—based on tumor specimens (including surgical and aspiration specimens). The absence of any of the four proteins confirms dMMR; a positive result for all four proteins indicates pMMR, i.e., complete mismatch repair function. Detection of MSI involves matching the lengths of repeated DNA sequences within tumor cells and somatic cells. When five standard loci are detected by PCR based on the US NCI standard, discordance in two or more loci indicates instability defined as MSI-H, one discordance loci indicates MSI-L, and five matching loci indicate MSS. Additionally, high-throughput sequencing (also referred to as next-generation sequencing or NGS) can be used as a method to detect microsatellite instability. When more microsatellite loci are selected, e.g., more than five loci or other microsatellite loci, for PCR assays, discordance in ≥ 30% of loci is defined as MSI-H, matching in all loci is defined as MSS, and discordance between 0% and 30% is defined as MSI-L.

[0161] Another aspect of the present invention is

[0162] A drug for blocking the binding of PD-1 to PD-L1,

[0163] A drug for downregulating the activity or level of PD-1,

[0164] A drug for alleviating PD-1 immunosuppression in an organism, or

[0165] Agents for increasing IFN-γ and / or IL-2 expression in T lymphocytes;

[0166] and / or

[0167] A drug for blocking the binding of CTLA4 to B7,

[0168] A drug for downregulating the activity or level of CTLA4,

[0169] A drug for alleviating the immunosuppression of CTLA4 in an organism, or

[0170] Drugs to increase IL-2 expression in T lymphocytes

[0171] The present invention relates to the use of a bispecific antibody or conjugate according to any embodiment of the present invention in the manufacture of [a substance].

[0172] Another aspect of the present invention relates to a method for preventing and / or treating and / or adjuvant treating and / or diagnosing a tumor, the method comprising the step of administering a bispecific antibody, conjugate, pharmaceutical composition, or combination product according to any embodiment of the present invention to a subject requiring treatment; preferably, the tumor is selected from one or more of melanoma, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, leukemia, breast cancer, mesothelioma, cervical cancer, endometrial cancer, lymphoma, and nasopharyngeal cancer;

[0173] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer, and squamous cell lung cancer;

[0174] Preferably, the gastric cancer is a gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma;

[0175] Preferably, the tumor is a solid tumor of the MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors of the MSI-H / dMMR phenotype: colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm.

[0176] In one or more embodiments of the present invention, in the case of the method, administration is before or after surgical treatment and / or before or after radiation therapy.

[0177] In one or more embodiments of the present invention, in the case of the method,

[0178] The unit dose of the bispecific antibody is 0.1-100 mg per kg of body weight, preferably 1-10 mg per kg of body weight; alternatively, the unit dose of the bispecific antibody is 10-1000 mg in each subject (e.g., about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg or about 1000 mg), preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg;

[0179] Preferably, the dosage is provided once every 3, 4, 5, 6, 10 days, 1 week, 2 weeks, or 3 weeks;

[0180] Preferably, the route of administration is intravenous drip infusion or intravenous injection.

[0181] In some embodiments, administration of the anti-CTLA4 / anti-PD-1 bispecific antibody is performed in cycles of 2 weeks (14 days) or 3 weeks (21 days), preferably, the anti-CTLA4 / anti-PD-1 bispecific antibody is administered intravenously on the first day (D1) of each cycle. For example, the anti-CTLA4 / anti-PD-1 bispecific antibody is administered once every 2 weeks (q2w) or once every 3 weeks (q3w).

[0182] Additionally, a bispecific antibody, conjugate, pharmaceutical composition, or combination product according to any embodiment of the present invention is provided for use in the prevention and / or treatment and / or adjuvant therapy and / or diagnosis of tumors; preferably, the tumor is selected from one or more of melanoma, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, leukemia, breast cancer, mesothelioma, cervical cancer, endometrial cancer, lymphoma, and nasopharyngeal cancer;

[0183] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer, and squamous cell lung cancer;

[0184] Preferably, the gastric cancer is a gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma;

[0185] Preferably, the tumor is a solid tumor of the MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors of the MSI-H / dMMR phenotype: colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm.

[0186] Blocking of PD-1 binding to PD-L1,

[0187] Downregulation of PD-1 activity or levels

[0188] Alleviation of PD-1 immunosuppression in organisms, or

[0189] Increased IFN-γ expression in T lymphocytes;

[0190] and / or

[0191] Blocking of CTLA4 binding to B7,

[0192] Downregulation of CTLA4 activity or levels

[0193] Alleviation of CTLA4 immunosuppression in organisms, or

[0194] Elevated IL-2 expression in T lymphocytes

[0195] A bispecific antibody or conjugate according to any embodiment of the present invention for use in is provided.

[0196] Antibody drugs, particularly monoclonal antibodies (mAbs), have demonstrated excellent efficacy in the treatment of various diseases. Traditional methods for obtaining therapeutic antibodies involve immunizing animals with antigens to produce antigen-specific antibodies or improving low-affinity antibodies through affinity maturation.

[0197] The variable regions of the light and heavy chains of an antibody determine the binding of the antibody to its antigen; the variable region of each chain includes three hypervariable regions, namely complementarity determining regions (CDRs) (the CDR of the heavy chain (H) includes HCDR1, HCDR2, and HCDR3, and the CDR of the light chain (L) includes LCDR1, LCDR2, and LCDR3; defined by Kabat et al., see reference (Sequences of Proteins of Immunological Interest, Fifth Edition (1991), 1-3, NIH Publication 91-3242, Bethesda Md)).

[0198] In (1) to (9) below, the amino acid sequences of the CDR regions of the monoclonal antibodies are analyzed by technical means widely known to those skilled in the art, for example, by the VBASE2 database, and the results are as follows:

[0199] (1) 14C12

[0200] The amino acid sequence of the heavy chain variable portion is described in SEQ ID NO. 14, and the amino acid sequence of the light chain variable portion is described in SEQ ID NO. 16.

[0201] The amino acid sequences of the three CDR regions of the heavy chain variable portion are as follows:

[0202] HCDR1: GFAFSSYD (Sequence No. 27)

[0203] HCDR2: ISGGGRYT (Sequence No. 28)

[0204] HCDR3: ANRYGEAWFAY (Sequence No. 29)

[0205] The amino acid sequences of the three CDR regions of the light chain variable portion are as follows:

[0206] LCDR1: QDINTY (Sequence No. 30)

[0207] LCDR2: RAN (Sequence No. 31)

[0208] LCDR3: LQYDEFPLT (Sequence No. 32)

[0209] (2) 14C12H1L1

[0210] The amino acid sequence of the heavy chain variable portion is described in SEQ ID NO. 18, and the amino acid sequence of the light chain variable portion is described in SEQ ID NO. 20.

[0211] The amino acid sequence of the three CDR regions of the heavy chain variable portion is identical to 14C12.

[0212] The amino acid sequence of the three CDR regions of the light chain variable portion is identical to 14C12.

[0213] (3) 4G10

[0214] The amino acid sequence of the heavy chain variable portion is described in SEQ ID No. 2, and the amino acid sequence of the light chain variable portion is described in SEQ ID No. 4.

[0215] The amino acid sequences of the three CDR regions of the heavy chain variable portion are as follows:

[0216] HCDR1: GYSFTGYT (Sequence No. 33)

[0217] HCDR2: INPYNNIT (Sequence No. 34)

[0218] HCDR3: ARLDYRSY (Sequence No. 35)

[0219] The amino acid sequences of the three CDR regions of the light chain variable portion are as follows:

[0220] LCDR1: TGAVTTSNF (Sequence No. 36)

[0221] LCDR2: GTN (Sequence No. 37)

[0222] LCDR3: ALWYSNHWV (Sequence No. 38)

[0223] (4) 4G10H1L1

[0224] The amino acid sequence of the heavy chain variable portion is described in SEQ ID No. 6, and the amino acid sequence of the light chain variable portion is described in SEQ ID No. 8;

[0225] The amino acid sequence of the three CDR regions of the heavy chain variable part is the same as 4G10.

[0226] The amino acid sequence of the three CDR regions of the light chain variable part is the same as 4G10.

[0227] (5) 4G10H3L3

[0228] The amino acid sequence of the heavy chain variable portion is described in SEQ No. 10, and the amino acid sequence of the light chain variable portion is described in SEQ No. 12.

[0229] The amino acid sequences of the three CDR regions of the heavy chain variable portion are identical to 4G10.

[0230] The amino acid sequences of the three CDR regions of the light chain variable portion are identical to 4G10.

[0231] (6) BiAb001(M)

[0232] The amino acid sequences of the 9 CDR regions associated with the heavy chain variable region are as follows:

[0233] HCDR1: GFAFSSYD (Sequence No. 27)

[0234] HCDR2: ISGGGRYT (Sequence No. 28)

[0235] HCDR3: ANRYGEAWFAY (Sequence No. 29)

[0236] HCDR4: GYSFTGYT (Sequence No. 33)

[0237] HCDR5: INPYNNIT (Sequence No. 34)

[0238] HCDR6: ARLDYRSY (Sequence No. 35)

[0239] HCDR7: TGAVTTSNF (Sequence No. 36)

[0240] HCDR8: GTN (Sequence No. 37)

[0241] HCDR9: ALWYSNHWV (Sequence No. 38)

[0242] The amino acid sequences of the three CDR regions associated with the light chain variable region are as follows:

[0243] LCDR1: QDINTY (Sequence No. 30)

[0244] LCDR2: RAN (Sequence No. 31)

[0245] LCDR3: LQYDEFPLT (Sequence No. 32)

[0246] (7) BiAb002(M)

[0247] The amino acid sequence of the 9 CDR regions associated with the heavy chain variable region is identical to BiAb001(M).

[0248] The amino acid sequence of the three CDR regions associated with the light chain variable region is identical to BiAb001(M).

[0249] (8) BiAb003(M)

[0250] The amino acid sequence of the 9 CDR regions associated with the heavy chain variable region is identical to BiAb001(M).

[0251] The amino acid sequence of the three CDR regions associated with the light chain variable region is identical to BiAb001(M).

[0252] (9) BiAb004(M)

[0253] The amino acid sequence of the 9 CDR regions associated with the heavy chain variable region is identical to BiAb001(M).

[0254] The amino acid sequence of the three CDR regions associated with the light chain variable region is identical to BiAb001(M).

[0255] In the case of the antibody BiAb004(hG1TM) of the present invention, amino acid mutations are introduced into the nonvariable portion of BiAb004(M). According to the EU numbering system, amino acid mutations are introduced at positions 234, 235, and 237:

[0256] BiAb004(hG1TM) is obtained by introducing a point mutation (L234A) changing leucine to alanine at position 234, a point mutation (L235A) changing leucine to alanine at position 235, and a point mutation (G237A) changing glycine to alanine at position 237 in the hinge region of the heavy chain.

[0257] Unless otherwise defined in this invention, the scientific and technical terms used in this application retain the meanings commonly understood by those skilled in the art. Additionally, the laboratory techniques of cell culture, molecular genetics, nucleic acid chemistry, and immunology used in this application are common procedures widely used in the corresponding fields. Meanwhile, to better understand the invention, relevant definitions and descriptions are provided below.

[0258] As used in this application, when referring to the amino acid sequence of the CTLA4 protein CTLA4 (cytotoxic T-lymphocyte antigen 4), this includes the full-length CTLA4 protein as well as the extracellular fragment of CTLA4, CTLA4ECD or a fragment containing CTLA4ECD; and also a fusion protein of CTLA4ECD fused to, for example, a fragment of mouse or human IgG Fc protein (mFc or hFc). However, a person skilled in the art will recognize that mutations or variations (including, but not limited to, substitutions, deletions, and / or additions) may occur naturally or be artificially introduced within the amino acid sequence of the CTLA4 protein. Accordingly, in this invention, the term “CTLA4 protein” includes all such sequences, including their natural or artificial variants. Additionally, when describing a sequence fragment of the CTLA4 protein, this also includes the corresponding sequence fragment within its natural or artificial variant.

[0259] As used in this application, when referring to the amino acid sequence of the PD-1 protein (NCBI GenBank: NM_005018), it includes the full-length PD-1 protein, or the extracellular fragment of PD-1, PD-1ECD, or a fragment containing PD-1ECD; it also includes a fusion protein of PD-1ECD, for example, a fragment fused to a mouse or human IgG Fc protein fragment (mFc or hFc). However, a person skilled in the art will recognize that mutations or variations (including, but not limited to, substitutions, deletions, and / or additions) within the amino acid sequence of the PD-1 protein may occur naturally or be artificially introduced without affecting its biological function. Accordingly, in this invention, the term "PD-1 protein" includes all such sequences, including their natural or artificial variants. Additionally, when describing a sequence fragment of the PD-1 protein, it also includes the corresponding sequence fragment within its natural or artificial variant.

[0260] As used in the present invention, unless otherwise specified, B7 is B7-1 and / or B7-2; specific sequences thereof are sequences known in the prior art, and reference may be made to sequences disclosed in existing literature and GenBank. For example, B7-1 (CD80, NCBI gene ID: 941); B7-2 (CD86, NCBI gene ID: 942).

[0261] As used in this application, the term "EC" 50 means the concentration for 50% of the maximum effect, that is, the concentration capable of producing 50% of the maximum effect.

[0262] As used in this application, the term "antibody" generally refers to an immunoglobulin molecule composed of two pairs of polypeptide chains (each pair consisting of one "light (L) chain" and one "heavy (H) chain). Generally, the heavy chain can be understood as the polypeptide chain having a larger molecular weight within the antibody, and the light chain refers to the polypeptide chain having a smaller molecular weight within the antibody. Light chains are classified as κ and λ light chains. Heavy chains are generally classified as μ, δ, γ, α, or ε heavy chains, and the isotypes of the antibody are defined as IgM, IgD, IgG, IgA, and IgE, respectively. In the light and heavy chains, the variable and constant regions are connected by a "J" region composed of about 12 or more amino acids, and the heavy chain also includes a "D" region of about 3 or more amino acids. Each heavy chain is a heavy chain variable region (V H ) and heavy chain invariant (C H It consists of ). The heavy chain invariant is composed of 3 domains (C H1 , C H2 , and C H3 It consists of ). Each light chain is composed of a light chain variable portion (V L ) and light chain invariant (C L It consists of ). The light chain invariant is a single domain C L It consists of. The constant part of the antibody can mediate the binding of immunoglobulin to host tissues or factors, including binding to the first component (C1q) of the classical complement system of various cells of the immune system (e.g., effector cells). Additionally, V H and V L The region is subdivided into a highly variable region (referred to as the Complementarity Decision Region (CDR)) distributed between conservative regions referred to as the Framework Region (FR). Each V H and V LIt consists of 3 CDRs and 4 FRs in the order FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from the amino terminus to the carboxyl terminus. The variable portion (V) of each heavy / light chain pair H and V L ) each form an antibody binding site. The assignment of amino acids to each region or domain is based on the literature (Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD. (1987 and 1991)), Chothia & Lesk, (1987) J. Mol. Biol. , 196:901-917, or Chothia et al. (1989) Nature It follows the definition of (342:878-883). In particular, the heavy chain may also contain more than 3, e.g., 6, 9, or 12 CDRs. For example, in the bispecific antibody of the present invention, the heavy chain may be an scFv having the C-terminus of the heavy chain of an IgG antibody linked to another antibody, in which case the heavy chain contains 9 CDRs. The term "antibody" is not limited by any particular method for producing the antibody. For example, antibodies include, in particular, recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody may be of different isotypes, e.g., IgG (e.g., subtypes IgG1, IgG2, IgG3, or IgG4), IgA1, IgA2, IgD, IgE, or IgM.

[0263] The antigen-binding fragment of the antibody (e.g., the antibody fragment mentioned above) may be obtained from an antibody provided using conventional techniques known to a person skilled in the art (e.g., DNA recombination, or enzymatic or chemical cleavage), and the antigen-binding fragment of the antibody is selected for specificity in the same manner as for an intact antibody.

[0264] As used in this application, where the term "antibody" refers to the antibody, unless otherwise evident from the context, it includes not only the intact antibody but also the antigen-binding fragment of the antibody.

[0265] As used in this application, the terms “mAb” and “monoclonal antibody” refer to an antibody or a fragment thereof derived from a group of highly homologous antibodies, that is, from a group of identical antibody molecules, excluding naturally occurring mutations. Monoclonal antibodies are highly specific for a single epitope on an antigen. Compared to monoclonal antibodies, polyclonal antibodies generally comprise at least two or more different antibodies that recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using hybridoma technology, as first reported by Kohler et al. (Nature, 256: 495, (1975)), but can also be obtained using DNA recombination (see, for example, U.S. Patent 4,816,567).

[0266] As used in the present invention, the term “humanized antibody” means an antibody or antibody fragment obtained when all or part of the CDR region of a human immunoglobulin (recipient antibody) is replaced by the CDR region of a non-human antibody (donor antibody), wherein the donor antibody may be a non-human (e.g., mouse, rat, or rabbit) antibody possessing the predicted specificity, affinity, or reactivity. Additionally, some amino acid residues of the framework region (FR) of the recipient antibody may also be replaced by amino acid residues of the corresponding non-human antibody or by amino acid residues of another antibody to further improve or optimize the performance of the antibody. For more detailed information on humanized antibodies, refer to, for example, the literature (Jones, et al., Nature, 321: 522-525(1986); Reichmann et al., Nature, 332: 323-329(1988); Presta, Curr. Op. Struct. Biol., 2: 593-596(1992); and Clark, Immunol. Today, 21: 397-402(2000)).

[0267] As used in the present invention, the term “epitope” refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. “Epitope” is also referred to as an “antigenic determinant” in the art. An epitope or antigenic determinant generally consists of a chemically active surface group of a molecule, e.g., an amino acid, a carbohydrate, or a sugar side chain, and generally possesses specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope generally consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or discontinuous amino acids in a unique spatial form that may be “linear” or “stereomorphic.” For example, refer to the literature (Epitope Mapping Protocols in Methods in Molecular Biology, volume 66, GE Morris, Ed. (1996)). In linear epitopes, all interaction sites between a protein and an interacting molecule (e.g., an antibody) are located linearly along the primary amino acid sequence of the protein. In stereotypic epitopes, interaction sites are located across the amino acid residues of the protein that are separated from each other.

[0268] As used in this invention, the term "isolated" means obtained from a natural state by artificial means. Where a specific "isolated" substance or component occurs naturally, this may be due to a change occurring in its natural environment, or it may be isolated from its natural environment, or both. For example, a specific unisolated polynucleotide or polypeptide exists within a specific living animal, and the same polynucleotide or polypeptide possessing high purity isolated from such natural state is referred to as an isolated polynucleotide or polypeptide. The term "isolated" does not exclude the presence of artificial or synthetic materials, or other impurities that do not affect activity.

[0269] As used in the present invention, the term "E. coli ( E . coli The term “expression system” refers to an expression system consisting of E. coli (strain) and a vector, wherein E. coli (strain) is derived from commercially available strains, e.g., GI698, ER2566, BL21(DE3), B834(DE3) and BLR(DE3), but is not limited to these.

[0270] As used in the present invention, the term "vector" means a nucleic acid delivery vehicle into which a polynucleotide can be inserted. If the vector enables the expression of a protein encoded by the inserted polynucleotide, the vector is referred to as an expression vector. The vector can be introduced into a host cell by transformation, transduction, or transfection so that the genetic material elements carried by the vector can be expressed within the host cell. Vectors are widely known to those skilled in the art and include, but are not limited to, plasmids; phages; cosmids; artificial chromosomes, e.g., yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); phages, e.g., lambda phage or M13 phage; and animal viruses. Animal viruses that may be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papovaviruses (e.g., SV40). The vector may contain various components for controlling expression, which include, but are not limited to, a promoter, a transcription initiation sequence, an enhancer sequence, a selection element, and a reporter gene. Additionally, the vector may also include a replication initiation site.

[0271] As used in the present invention, the term "host cell" means a cell into which a vector can be introduced, which is a eukaryotic cell, e.g. E. coli and Bacillus subtilis ( Bacillus subtilis ), fungal cells, for example, yeast cells and Aspergillus ( AspergillusInsect cells, e.g., S2 drosophila cells and Sf9, or animal cells, e.g., fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells, or human cells, but are not limited to these.

[0272] As used in the present invention, the term “specifically bind” refers to a non-random binding reaction between two molecules, for example, a reaction between an antibody and an antigen that the antibody targets. In some embodiments, the antibody that specifically binds to the antigen (or the antibody specific to the antigen) is about 10 -5 Less than M, e.g., 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, or 10 -10 Affinity less than or equal to M (K D It refers to an antibody that binds to an antigen. In some embodiments of the present invention, the term "target" means specific binding.

[0273] As used in the present invention, the term "K D " refers to the dissociation equilibrium constant for a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the more robust the antibody-antigen binding becomes, and the higher the affinity between the antibody and the antigen. Generally, antibodies are approximately 10, as measured, for example, by the BIACORE Surface Plasmon Resonance (SPR) instrument or the ForteBio Octet system -5 Less than M, for example, about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M, or a dissociation equilibrium constant less than that (K D It binds to the antigen.

[0274] As used in the present invention, the terms "monoclonal antibody" and "mAb" have the same meaning and may be used interchangeably; the terms "polyclonal antibody" and "pAb" have the same meaning and may be used interchangeably; and the terms "polypeptide" and "protein" have the same meaning and may be used interchangeably. Additionally, in the present application, amino acids are generally represented by single letters or three-letter abbreviations known in the art. For example, alanine may be represented as A or Ala.

[0275] As used in the present invention, the term “pharmaceutically acceptable carrier and / or excipient” means a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the target and active ingredient, which is widely known in the art (see, for example, Remington's Pharmaceutical Sciences Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffer; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, for example, Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.

[0276] As used in the present invention, the term "adjuvant" refers to a non-specific immune enhancer that, when delivered to the body together with or before the antigen, can enhance the body's immune response to the antigen or alter the type of immune response. Aluminum adjuvants (e.g., aluminum hydroxide), Freund adjuvants (e.g., full Freund adjuvants and incomplete Freund adjuvants), Corynebacterium parvum ( Corynebacterium parvum There are numerous adjuvants, including but not limited to lipopolysaccharides, cytokines, etc. Freund's adjuvant is the most commonly used adjuvant in animal studies. Aluminum hydroxide adjuvants are more commonly used in clinical trials.

[0277] As used in the present invention, the term "effective dose" means an amount sufficient to obtain the desired effect, or at least partially obtain it. For example, a prophylactic effective dose (e.g., for a disease associated with the binding of CTLA4 to B7 or hyperresponsiveness of CTLA4, e.g., a tumor) is an amount sufficient to prevent, stop, or delay the onset of the disease (e.g., a disease associated with hyperresponsiveness of CTLA4 binding to B7 or a disease associated with hyperresponsiveness of CTLA4, e.g., a tumor); and a therapeutic effective dose is an amount sufficient to cure the disease and its complications in a patient suffering from the disease, or at least partially stop them. Determining such effective doses is undoubtedly within the scope of ability of a person skilled in the art. For example, the effective dose for therapeutic purposes will depend on the severity of the disease to be treated, the overall condition of the patient's own immune system, the patient's general background, e.g., age, weight, and sex, the route of administration, and other treatments provided concurrently.

[0278] "Recurrent" cancer is cancer that recurs in a different site after a response to the original site or previous treatment (e.g., surgery). "Locally recurrent" cancer is cancer that develops in the same site after treatment for previously treated cancer.

[0279] "Metastatic" cancer refers to cancer that spreads from one part of the body (e.g., the lungs) to another.

[0280] As used in this application, “completely removed” means a very weak binding signal or the absence of a binding signal as detected by conventional measurements (e.g., the ForteBio Octet system). In one embodiment of the invention, the absence of a binding signal or a very weak binding signal means a binding signal (i.e., a response value) of less than 0.1 nm.

[0281] In the present invention, the terms "first" (e.g., first protein functional region, first linker fragment, or first product) and "second" (e.g., second protein functional region, second linker fragment, or second product) are used for distinction or clarity of expression and do not retain a typical sequential meaning unless otherwise specified.

[0282] In the present invention, "about" or "approximately" means that a defined value or physical quantity varies within a range of 10%, 20%, or 30% unless otherwise specified. For example, about 100 minutes or about 100 minutes may be 90 to 110 minutes, 80 to 12 minutes, or 70 to 130 minutes.

[0283] Advantages of the present invention:

[0284] The present invention achieves one or more of the following technical effects (1) to (3):

[0285] (1) Modification of the Fc fragment of the antibody of the present invention by the inventors removes ADCC activity and / or ADCP activity by completely removing the binding activity of BiAb004(hG1TM) to FcγRI, FcγRIIa_H131, FcγRIIIa_V158 and / or FcγRIIIa_F158.

[0286] (2) Modification of the Fc fragment of the antibody of the present invention by the inventors eliminates CDC activity by completely eliminating binding activity to complement C1q.

[0287] (3) The antibody of the present invention has the potential to be used in the manufacture of drugs for preventing and treating tumors. Brief explanation of the drawing

[0288] Fig. 1: Affinity constant assay of BiAb004(hG1TM) for FcγRI. The antibody concentrations for the pairs of curves from top to bottom are 50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.12 nM, respectively. Fig. 2: Affinity constant assay of BiAb004(hG1WT) for FcγRI. The antibody concentrations for the pairs of curves from top to bottom are 50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.12 nM, respectively. Fig. 3: Affinity constant assay of BiAb004(hG1TM) for FcγRIIIa_V158. The antibody concentrations for the curve pairs from top to bottom are 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM, respectively. Fig. 4: Affinity constant assay of BiAb004(hG1WT) for FcγRIIIa_V158. The antibody concentrations for the curve pairs from top to bottom are 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM, respectively. Fig. 5: Affinity constant assay of BiAb004(hG1TM) for FcγRIIIa_F158. The antibody concentrations for the curve pairs from top to bottom are 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM, respectively. Fig. 6: Affinity constant assay of BiAb004(hG1WT) for FcγRIIIa_F158. The antibody concentrations for the curve pairs from top to bottom are 500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM, respectively. Fig. 7: Affinity constant assay of BiAb004(hG1TM) for FcγRIIa_H131. The antibody concentrations for the pairs of curves from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 8: Affinity constant assay of BiAb004(hG1WT) for FcγRIIa_H131. The antibody concentrations for the curve pairs from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 9: Affinity constant assay of BiAb004(hG1TM) for FcγRIIa_R131. The antibody concentrations for the curve pairs from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 10: Affinity constant assay of BiAb004(hG1WT) for FcγRIIa_R131. The antibody concentrations for the pairs of curves from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 11: Affinity constant assay of BiAb004(hG1TM) for FcγRIIb. The antibody concentrations for the pairs of curves from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 12: Affinity constant assay of BiAb004(hG1WT) for FcγRIIb. The antibody concentrations for the pairs of curves from top to bottom are 200 nM, 100 nM, 50 nM, 25 nM, and 12.5 nM, respectively. Fig. 13: Affinity constant assay of BiAb004(hG1TM) for C1q. The antibody concentrations for the curve pairs from top to bottom are 20 nM, 10 nM, 5 nM, 2.5 nM, and 1.25 nM, respectively. Fig. 14: Affinity constant assay of BiAb004(hG1WT) for C1q. The antibody concentrations for the pairs of curves from top to bottom are 20 nM, 10 nM, 5 nM, 2.5 nM, and 1.25 nM, respectively. Fig. 15: Affinity constant assay of 5C10H2L2-IgG1mt for C1q. The antibody concentrations for the pairs of curves from top to bottom are 20 nM, 10 nM, 5 nM, 2.5 nM, and 1.25 nM, respectively. Fig. 16: ADCC activity assay of BiAb004(hG1WT) and BiAb004(hG1TM) on 293T-CTLA4-PD1 cells expressing CTLA-4 and PD-1 antigens. Fig. 17: Inhibition of subcutaneous human lung cancer HCC827 cell tumor xenograft by BiAb004(hG1TM) with lenvatinib. Fig. 18: Inhibition of subcutaneous colon cancer MC38-hPDL1 / hCD73 tumor grafts by BiAb004(hG1TM) in C57BL / 6-hPD1 / hPDL1 / hCD73 mice. Fig. 19: Antibody-mediated phagocytic activity of BiAb004(hG1TM) against CHO-K1-PD1. Fig. 20: Significantly enhanced immune response of immune cells against human gastric cancer KATO III cells by BiAb004(hG1TM). Fig. 21: Significantly enhanced immune response of immune cells against human cervical cancer Hera cells by BiAb004(hG1TM). Fig. 22: Significantly enhanced immune response of immune cells against human T-cell lymphoma Jurkhat cells by BiAb004(hG1TM). Fig. 23: Significantly enhanced immune response of immune cells against human nasopharyngeal carcinoma CNE-2Z cells by BiAb004(hG1TM). Fig. 24: Significantly enhanced immune response of immune cells against human breast cancer MDA-MB-231 cells by BiAb004(hG1TM). Fig. 25: Significantly enhanced immune response of immune cells against human mesothelioma NCI-H2452 cells by BiAb004(hG1TM). Fig. 26: Significantly enhanced immune response of immune cells against human non-small cell lung cancer (human lung adenocarcinoma) A549 cells by BiAb004 (hG1TM) with anlotinib. Fig. 27: Significantly enhanced immune response of immune cells against human small cell lung cancer NCI-H446 cells by BiAb004(hG1TM) with anlotinib. Fig. 28: Significantly enhanced immune response of immune cells against human squamous cell lung cancer NCI-H226 cells by BiAb004(hG1TM) with anlotinib. Fig. 29: Significantly enhanced immune response of immune cells against human colorectal cancer SW48 cells of the MSI-H / dMMR phenotype by BiAb004(hG1TM). Fig. 30: Significantly enhanced immune response of immune cells against human colorectal cancer SW837 cells with MSI-H / dMMR phenotype by BiAb004(hG1TM). Specific details for implementing the invention

[0289] Embodiments of the present invention will be described in detail below with reference to the examples. Those skilled in the art will understand that the following examples are used merely to illustrate the invention and are not to be construed as limiting the scope of the invention. Where techniques and conditions are not specifically stated, the examples were performed according to techniques or conditions described in literature in the art (e.g., Molecular Cloning: A Laboratory Manual, written by J. Sambrook et al. and translated by Huang Peitang et al., 3rd edition, Science Press) or according to product manuals. The reagents and equipment used are commercially available standard products unless their manufacturers are specifically stated.

[0290] In the embodiments of the present invention described below,

[0291] BALB / c mice were purchased from Guangdong Medical Laboratory Animal Center.

[0292] Human peripheral blood mononuclear cells were isolated and manufactured by Akeso Biopharma, Inc. with the donor's consent.

[0293] Raji-PDL1 is a human PD-L1-expressing cell constructed by Akeso Biopharma, Inc. based on human B cell Raji by transfection.

[0294] Ficoll-Paque TM PLUS (or Ficoll-Paque PLUS) was purchased from GE Healthcare.

[0295] The human IL-2 ELISA kit was purchased from Dakewe Biotech Co., Ltd.

[0296] RPMI 1640 medium, DMEM medium, trypsin-EDTA (0.25%) phenol red, and blastidin were all purchased from Gibco.

[0297] Staphilococcus aureus Staphylococcus aureus ) Endotoxin B (SEB) was purchased from Dianotech.

[0298] FBS was purchased from Excell Bio.

[0299] Mitomycin C (MMC) was purchased from Stressmarq.

[0300] The sequence of the isotype control human anti-hen egg lysozyme IgG (anti-HEL antibody, or human IgG, abbreviated as hIgG) is from the literature (Acierno et al., title "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antiodyne" (Acierno et al., J Mol Biol. It is derived from the variable part sequence of the Fab F10.6.6 sequence in the study reported by , 2007; 374(1): 130-146).

[0301] The anlotinib used in the examples is a hydrochloride salt of anlotinib with the brand name Fukewei® and the generic name anlotinib hydrochloride, and was purchased from CTTQ Pharma.

[0302] The lenvatinib used in the examples is lenvatinib mesylate with the brand name Lenvima®, and was purchased from Eisai (China).

[0303] Preparation Example 1: Sequence Design of Anti-CTLA4 Antibody

[0304] The amino acid sequences and coding nucleotide sequences of the heavy and light chains of the anti-CTLA4 antibody 4G10 and its humanized antibodies 4G10H1L1 and 4G10H3L3 are identical to those of 4G10, 4G10H1L1 and 4G10H3L3 of Chinese Patent Publication CN106967172A, respectively.

[0305] (1) Sequence of the heavy and light chain variable portions of 4G10

[0306] Nucleotide sequence of the variable heavy chain: (372 bp)

[0307]

[0308] Encoded amino acid sequence: (124 aa)

[0309]

[0310] Nucleotide sequence of the variable portion of the light chain: (378 bp)

[0311]

[0312] Encoded amino acid sequence: (126 aa)

[0313]

[0314] (2) Heavy chain and light chain variable region sequences of humanized monoclonal antibody 4G10H1L1

[0315] Nucleotide sequence of the heavy chain variable region (4G10H1V): (345 bp)

[0316]

[0317] Encoded amino acid sequence: (115 aa)

[0318]

[0319] Nucleotide sequence of the light chain variable region (4G10L1V): (327 bp)

[0320]

[0321] Encoded amino acid sequence: (109 aa)

[0322]

[0323] (3) Heavy chain and light chain variable region sequences of humanized monoclonal antibody 4G10H3L3

[0324] Nucleotide sequence of the heavy chain variable region (4G10H3V): (345 bp)

[0325]

[0326] Encoded amino acid sequence (4G10H3V): (115 aa)

[0327]

[0328] Nucleotide sequence of the light chain variable region (4G10L3V): (327 bp)

[0329]

[0330] Encoded amino acid sequence (4G10L3V): (109 aa)

[0331]

[0332] Preparation Example 2: Sequence Design of Anti-PD-1 Antibody 14C12 and Its Humanization Antibody 14C12H1L1

[0333] The amino acid sequences and coding nucleotide sequences of the anti-PD-1 antibody 14C12 and its humanized antibody 14C12H1L1 are identical to those of 14C12 and 14C12H1L1 in Chinese Patent Publication CN106967172A, respectively.

[0334] (1) Sequence of the heavy and light chain variable portions of 14C12

[0335] Nucleotide sequence of the variable heavy chain: (354 bp)

[0336]

[0337] Encoded amino acid sequence: (118 aa)

[0338]

[0339] Nucleotide sequence of the variable portion of the light chain: (321 bp)

[0340]

[0341] Encoded amino acid sequence: (107 aa)

[0342]

[0343] (2) Heavy and light chain variable portions and heavy and light chain sequences of humanized monoclonal antibody 14C12H1L1

[0344] Nucleotide sequence of the variable heavy chain: (354 bp)

[0345]

[0346] Encoded amino acid sequence: (118 aa)

[0347]

[0348] Nucleotide sequence of the variable portion of the light chain: (321 bp)

[0349]

[0350] Encoded amino acid sequence: (107 aa)

[0351]

[0352] DNA sequence of the 14C12H1L1 heavy chain (14C12H1): (1344 bp)

[0353]

[0354] Encoded amino acid sequence: (448 aa)

[0355]

[0356] DNA sequence of the 14C12H1L1 light chain (14C12L1): (642 bp)

[0357]

[0358] Encoded amino acid sequence: (214 aa)

[0359]

[0360] Preparation Example 3: Sequence design of dual-function antibodies BiAb001(M), BiAb002(M), BiAb003(M), and BiAb004(M)

[0361] The structural pattern of the dual-acting antibodies BiAb001(M), BiAb002(M), BiAb003(M), and BiAb004(M) is the Morrison format (IgG-scFv), meaning that the C-terminuses of the two heavy chains of one IgG antibody are separately linked to the scFv fragment of the other antibody by a linker fragment. The components for the heavy and light chain design are shown in Table A below.

[0362] [Table A]

[0363]

[0364] In Table A above,

[0365] The amino acid sequence of linker 1 is (GGGGS)3 (sequence number 25), and

[0366] The amino acid sequence of linker 2 is (GGGGS)4 (sequence number 26).

[0367] In Table A above, the scFv fragments 4G10H1V(M), 4G10L1V(M), 4G10H3V(M), and 4G10L3V(M) of BiAb001(M), BiAb002(M), BiAb003(M), and BiAb004(M) antibodies contained mutations within individual amino acids of the framework region based on 4G10H1V, 4G10L1V, 4G10H3V, and 4G10L3V, respectively, which effectively optimized the structure of the antibodies and improved their efficacy.

[0368] (1) 4G10H1V(M): (115 aa, mutation site is underlined in the amino acid sequence based on 4G10H1V)

[0369]

[0370] (2) 4G10L1V(M): (110 aa, mutation site is underlined in the amino acid sequence based on 4G10L1V)

[0371]

[0372] (3) 4G10H3V(M): (115 aa, mutation site is underlined in the amino acid sequence based on 4G10H3V)

[0373]

[0374] (4) 4G10L3V(M): (110 aa, mutation site is underlined in the amino acid sequence based on 4G10L3V)

[0375]

[0376] To distinguish it from the mutated antibody below, BiAb004(M) is also referred to as BiAb004(hG1WT) in this embodiment. The BiAb004(M) described above is the "wild type" and comprises an Ig gamma-1 chain C region (accession number: P01857) as a heavy chain constant and an Ig kappa chain C region (accession number: P01834) as a light chain constant.

[0377] Preparation Example 4: Design of a non-variable region amino acid mutation based on the humanized dual-acting antibody BiAb004

[0378] Based on BiAb004(hG1WT) obtained in Preparation Example 3, BiAb004(hG1TM) was obtained by introducing a point mutation (L234A) changing leucine to alanine at position 234 in the heavy chain, a point mutation (L235A) changing leucine to alanine at position 235, and a point mutation (G237A) changing glycine to alanine at position 237.

[0379] DNA sequence of the heavy chain of the immunoglobulin moiety in BiAb004(hG1TM): (1344 bp, mutation site is underlined)

[0380]

[0381] Amino acid sequence of the heavy chain of the immunoglobulin moiety in BiAb004(hG1TM): (448 bp, mutation site is underlined)

[0382]

[0383] BiAb004(hG1TM) and BiAb004(hG1WT) share the same DNA sequence of the light chain and the same coded amino acid sequence. The specific sequence is shown in Preparation Example 3.

[0384] Experimental Example 1: Affinity assay of BiAb004(hG1WT) and BiAb004(hG1TM) for receptor FcγRI

[0385] Fc receptor FcγRI, also known as CD64, is associated with antibody-dependent cell-mediated cytotoxicity (ADCC). The binding ability of therapeutic monoclonal antibodies to the Fc receptor will affect the safety and efficacy of the antibodies.

[0386] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRI were measured in this experiment using the ForteBio Octet system to evaluate the potential ADCC and ADCP activities of the antibodies.

[0387] The method for determining the affinity constant of an antibody for FcγRI by the ForteBio Octet system is schematically described as follows: The sample dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. A 1 μg / mL FcγRI solution (purchased from Sinobio) was added to the sensor to immobilize FcγRI on the surface of the HIS1K sensor for 50 s. The binding and dissociation constants of the antibody for FcγRI were both determined using antibody concentrations of 3.12–50 nM (sequential 2-fold dilution) within the buffer. The sensor holding the immobilized antigen was equilibrated in the buffer for 60 s, and subsequently, the binding of FcγRI immobilized on the sensor to the antibody was determined for 120 s; and the dissociation of FcγRI from the antibody was determined within 120 s. The temperature was 30°C, and the frequency was 0.3 Hz. To obtain the affinity constant for FcγRI to the antibody, the data were fitted and analyzed using a 1:1 model.

[0388] The results of the affinity constant assays for BiAb004(hG1TM) and BiAb004(hG1WT) against FcγRI are shown in Table 1 and Figures 1 and 2 below.

[0389]

[0390] The above results indicated that BiAb004(hG1WT) was bound to FcγRI with an affinity constant of 5.92E-09 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained or a very weak signal for FcγRI was detected, which indicates no binding to FcγRI.

[0391] The above results suggest that the binding activity of BiAb004(hG1TM) to FcγRI is effectively removed compared to BiAb004(hG1WT).

[0392] Experimental Example 2: Affinity Constant Assay of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIIa_V158

[0393] The Fc receptor FcγRIIIa_V158 (also known as CD16a_V158) can bind to the Fc fragment of an IgG antibody and mediate the ADCC effect.

[0394] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIIa_V158 were measured in this experiment using the ForteBio Octet system to evaluate the ADCC activity of the antibodies.

[0395] The method for determining the affinity constant of an antibody against FcγRIIIa_V158 by the ForteBio Octet system is schematically described as follows: The sample dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIIa_V158 was immobilized on the surface of the HIS1K sensor for 50 s. The sensor was equilibrated in the buffer for 60 s, and binding of the antibody to FcγRIIIa_V158 immobilized on the sensor at concentrations of 31.25–500 nM (sequential 2-fold dilution) was determined for 60 s. The antibody dissociated in the buffer for 60 s. The sensor was refreshed four times in 10 mM glycine pH 1.5 for 5 s each. The temperature was 30°C, and the frequency was 0.3 Hz. The data was analyzed by 1:1 model fitting to obtain the affinity constant.

[0396] The results of the affinity constant assays for BiAb004(hG1WT) and BiAb004(hG1TM) against FcγRIIIa_V158 are shown in Table 2 and Figures 3 and 4 below.

[0397]

[0398] The above results indicated that BiAb004(hG1WT) was bound to FcγRIIIa_V158 with an affinity constant of 1.77E-07 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained, or a very weak signal for FcγRIIIa_V158 was detected, which indicates no binding to FcγRIIIa_V158.

[0399] The above results suggest that the binding activity of BiAb004(hG1TM) to FcγRIIIa_V158 is effectively removed compared to BiAb004(hG1WT).

[0400] Experimental Example 3: Affinity constant assay of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIIa_F158

[0401] The Fc receptor FcγRIIIa_F158 (also known as CD16a_F158) can bind to the Fc fragment of an IgG antibody and mediate the ADCC effect.

[0402] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIIa_F158 were measured in this experiment using the ForteBio Octet system to evaluate the ADCC activity of the antibodies.

[0403] The method for determining the affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIIa_F158 by the ForteBio Octet system is schematically described as follows: The sample dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIIa_F158 was immobilized on the surface of the HIS1K sensor for 50 s. The sensor was equilibrated in the buffer for 60 s, and binding of the FcγRIIIa_F158 immobilized on the sensor to antibodies at concentrations of 31.25–500 nM (sequential 2-fold dilution) was determined for 60 s. The antibodies dissociated in the buffer for 60 s. The sensor was refreshed four times in 10 mM glycine pH 1.5 for 5 s each. The temperature was 30℃ and the frequency was 0.3 Hz. The data was analyzed by 1:1 model fitting to obtain the affinity constant.

[0404] The results of the affinity constant assays for BiAb004(hG1WT) and BiAb004(hG1TM) against FcγRIIIa_F158 are shown in Table 3 and Figures 5 and 6 below.

[0405]

[0406] The above results indicated that BiAb004(hG1WT) was bound to FcγRIIIa_F158 with an affinity constant of 1.77E-07 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained, or a very weak signal for FcγRIIIa_F158 was detected, which indicates no binding to FcγRIIIa_F158.

[0407] The above results suggest that the binding activity of BiAb004(hG1TM) to FcγRIIIa_F158 is effectively removed compared to BiAb004(hG1WT).

[0408] Experimental Example 4: Affinity constant assay of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_H131

[0409] The Fc receptor FcγRIIa_H131 (also known as CD32a_H131) can bind to the Fc fragment of IgG antibodies and mediate the ADCC effect.

[0410] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_H131 were measured in this experiment using the ForteBio Octet system to evaluate the ADCC activity of the antibodies.

[0411] The method for determining the affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_H131 by the ForteBio Octet system is schematically described as follows: the immobilization dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4, and the analyte dilution buffer was a solution of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIa_H131 was immobilized on the surface of the NTA sensor with an immobilization height of approximately 1.0 nm. The sensor was equilibrated for blocking for 300 s in a buffer of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4, and binding to antibodies at concentrations of 12.5–200 nM (sequential 2-fold dilutions) of FcγRIIa_H131 immobilized on the sensor was determined for 60 s. The antibodies dissociated in the buffer for 60 s. The sensor was refreshed in 10 mM glycine, pH 1.7, and 10 nM nickel sulfate. The temperature was 30°C, and the frequency was 0.6 Hz. The data were analyzed by 1:1 model fitting to obtain the affinity constants.

[0412] The results of the affinity constant assays for BiAb004(hG1WT) and BiAb004(hG1TM) against FcγRIIa_H131 are shown in Table 4 and Figures 7 and 8 below.

[0413]

[0414] The above results indicated that BiAb004(hG1WT) was bound to FcγRIIa_H131 with an affinity constant of 2.22E-08 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained, or a very weak signal for FcγRIIa_H131 was detected, which indicates no binding to FcγRIIa_H131.

[0415] The above results suggest that the binding activity of BiAb004(hG1TM) to FcγRIIa_H131 is effectively removed compared to BiAb004(hG1WT).

[0416] Experimental Example 5: Affinity constant assay of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_R131

[0417] The Fc receptor FcγRIIa_R131 (also known as CD32a_R131) can mediate the ADCC effect by binding to the Fc fragment of an IgG antibody.

[0418] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_R131 were measured in this experiment using the ForteBio Octet system to evaluate the ADCC activity of the antibodies.

[0419] The method for determining the affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIa_R131 by the ForteBio Octet system is schematically described as follows: the immobilization dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4, and the analyte dilution buffer was a solution of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIa_R131 was immobilized on the surface of the NTA sensor with an immobilization height of approximately 1.0 nm. The sensor was equilibrated for blocking for 300 s in a buffer of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4, and binding to antibodies at concentrations of 12.5–200 nM (sequential 2-fold dilutions) of FcγRIIa_R131 immobilized on the sensor was determined for 60 s. The antibodies dissociated in the buffer for 60 s. The sensor was refreshed in 10 mM glycine, pH 1.7, and 10 nM nickel sulfate. The temperature was 30°C, and the frequency was 0.6 Hz. The data were analyzed by 1:1 model fitting to obtain the affinity constants.

[0420] The results of the affinity constant assays for BiAb004(hG1WT) and BiAb004(hG1TM) against FcγRIIa_R131 are shown in Table 5 and Figures 9 and 10 below.

[0421]

[0422] The above results indicated that both BiAb004(hG1WT) and BiAb004(hG1TM) were coupled to FcγRIIa_R131 with affinity constants of 1.43E-08 M and 4.20E-08 M, respectively.

[0423] The above results suggest that both BiAb004(hG1WT) and BiAb004(hG1TM) possess binding activity for FcγRIIa_R131. However, the results in Figures 9 and 10 indicated that BiAb004(hG1WT) possesses a stronger binding signal and, therefore, has a higher affinity than BiAb004(hG1TM).

[0424] Experimental Example 6: Affinity constant assay of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIb

[0425] The Fc receptor FcγRIIb (also known as CD32a) can bind to the Fc fragment of IgG antibodies, downregulate the function of immune cells, inhibit the activation and proliferation of immune cells, and inhibit the secretion of cytokines.

[0426] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIb were measured in this experiment using the ForteBio Octet system to evaluate the binding ability of BiAb004(hG1WT) and BiAb004(hG1TM) to the Fc receptor.

[0427] The method for determining the affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for FcγRIIb by the ForteBio Octet system is schematically described as follows: the immobilization dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4, and the analyte dilution buffer was a solution of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4. 5 μg / mL of FcγRIIb was immobilized on the surface of the NTA sensor with an immobilization height of approximately 1.0 nm. The sensor was equilibrated for blocking for 300 s in a buffer of PBS, 0.02% Tween-20, 0.02% casein, and 0.1% BSA, pH 7.4, and binding to antibodies at concentrations of 12.5–200 nM (sequential 2-fold dilutions) of FcγRIIb immobilized on the sensor was determined for 60 s. The antibodies dissociated in the buffer for 60 s. The sensor was refreshed in 10 mM glycine, pH 1.7, and 10 nM nickel sulfate. The temperature was 30°C, and the frequency was 0.6 Hz. The data were analyzed by 1:1 model fitting to obtain the affinity constants.

[0428] The results of the affinity constant assays for BiAb004(hG1WT) and BiAb004(hG1TM) against FcγRIIb are shown in Table 6 and Figures 11 and 12 below.

[0429]

[0430] The above results indicated that BiAb004(hG1WT) was bound to FcγRIIb with an affinity constant of 5.61E-08 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained or a very weak signal for FcγRIIb was detected, which indicates no binding to FcγRIIb.

[0431] The above results suggest that the binding activity of BiAb004(hG1TM) to FcγRIIb is effectively removed compared to BiAb004(hG1WT).

[0432] Experimental Example 7: Affinity constant assay of BiAb004(hG1WT) and BiAb004(hG1TM) for C1q

[0433] Serum complement C1q can mediate the CDC effect by binding to the Fc fragment of IgG antibodies. The binding ability of therapeutic monoclonal antibodies to C1q will affect the safety and efficacy of said antibodies.

[0434] The affinity constants of BiAb004(hG1WT) and BiAb004(hG1TM) for C1q were measured in this experiment using the ForteBio Octet system to evaluate the CDC activity of the antibodies. In this experimental example, the anti-PDL1 antibody 5C10H2L2-IgG1mt was used as a control, and its preparation is described in PCT International Publication WO2017148424A1.

[0435] The method for determining the affinity constant of the antibody for C1q by the ForteBio Octet system is schematically described as follows: The sample dilution buffer was a solution of PBS, 0.02% Tween-20, and 0.1% BSA, pH 7.4. 50 μg / mL of antibody was immobilized on the FAB2G sensor with an immobilization height of approximately 2.0 nm. The sensor was equilibrated in the buffer for blocking for 60 s, and binding of the antibody immobilized on the sensor to antigen C1q at concentrations of 1.25–20 nM (sequential 2-fold dilution) was determined for 60 s. The antigen and antibody dissociated in the buffer for 60 s. The sensor was refreshed four times in 10 mM glycine pH 1.7 for 5 s each. The shaking speed of the sample plate was 1000 rpm, the temperature was 30°C, and the frequency was 0.6 Hz. The data was analyzed by 1:1 model fitting to obtain affinity constants. The data acquisition software was Fortebio Data Acquisition 7.0, and the data analysis software was Fortebio Data Analysis 7.0.

[0436] The results of the affinity constant assays for BiAb004(hG1WT), BiAb004(hG1TM), and 5C10H2L2-IgG1mt for C1q are shown in Table 7 and Figures 13, 14, and 15 below.

[0437]

[0438] The above results indicated that BiAb004(hG1WT) was bound to C1q with an affinity constant of 2.53E-09 M; meanwhile, for BiAb004(hG1TM), no data corresponding to no reaction signal was obtained or a very weak signal for C1q was detected, which indicates no binding to C1q.

[0439] The above results suggest that the binding activity of BiAb004(hG1TM) to C1q is effectively removed compared to BiAb004(hG1WT).

[0440] Experimental Example 8: ADCC activity assay of BiAb004(hG1WT) and BiAb004(hG1TM) on 293T-CTLA4-PD1 cells expressing CTLA4 and PD-1 antigens

[0441] The ADCC effect refers to the direct killing of target cells by effector immune cells possessing apoptotic activity, which recognize the Fc fragment of an antibody bound to the antigen of a target cell through Fc receptors (FcR) expressed on their surface. To test the ADCC effect of the anti-CTLA4 / anti-PD-1 dual-acting antibodies BiAb004 (hG1WT) and BiAb004 (hG1TM), the inventors established a co-culture system of 293T-CTLA4-PD1 cells expressing PD-1 and CTLA4 antigens and basic PBMCs to test the ADCC activity of said antibodies.

[0442] The method for the ADCC activity assay of BiAb004(hG1WT) and BiAb004(hG1TM) on 293T-CTLA4-PD1 cells expressing PD-1 and CTLA4 antigens is as follows:

[0443] Normal human PBMCs were isolated according to the Ficoll guidelines for the isolation of peripheral blood mononuclear cells. The isolated PBMCs were resuspended in RPMI-1640 complete medium, stained with AO / PI, counted, and frozen. One day prior to the experiment, the PBMCs were thawed and counted, and viability was determined. The cells were cultured overnight in a carbon dioxide incubator at 5% CO2 and 37°C. On the day of the experiment, 293T-CTLA4-PD1 cells and PBMCs were collected, centrifuged at 800 rpm or 1200 rpm for 5 minutes, resuspended in RPMI-1640 (containing 1% FBS; hereinafter referred to as the medium), and washed twice. The cells were counted, and viability was determined. Cell density was adjusted to an appropriate range using the medium. 100 μL of 293T-CTLA4-PD1 cells were added to a 96-well plate at a density of 3.0E+04 cells / well according to the experimental design. 50 μL of antibody was added, and the cells were pre-cultured at room temperature for 1 h; after 1 h, 50 μL of PBMC was added to a density of 9.0E+05 cells / well, the mixture was well mixed, and incubated at 37°C for 4 h in a 5% CO2 incubator. The cells were centrifuged at 250 xg for 5 min. 100 μL of the supernatant was transferred to a new 96-well flat-bottom microplate (cell sediment was not pipetteed). 100 μL of the freshly prepared reaction solution was added to each well according to the cytotoxicity detection kit instructions. The cells were incubated in the dark at room temperature for 30 min. OD values ​​were measured at 490 nm and 650 nm. The ADCC percentage was calculated for each group according to the formula ADCC(%) = (treatment group - negative control) / (maximum LDH release from target cells - natural LDH release from target cells) x 100%.

[0444] The ADCC activity of BiAb004(hG1WT) and BiAb004(hG1TM) on 293T-CTLA4-PD1 cells expressing CTLA4 and PD-1 antigens was expressed as ADCC percentage, and the results are shown in Figure 16.

[0445] The above results indicated that in a mixed culture system of PBMC and 293T-CTLA4-PD1, the percentage of ADCC induced by BiAb004(hG1TM) was significantly lower than the percentage of ADCC induced by BiAb004(hG1WT) at the same level.

[0446] The above results suggest that BiAb004(hG1TM) does not possess ADCC activity.

[0447] Experimental Example 9: Inhibition of growth of colorectal cancer MC38 cell transplants in mice by BiAb004(hG1TM) with lenvatinib

[0448] The mouse MC38 cell line is a mouse colorectal cancer cell line. The MC38 cell line has been proven to be a useful model for studying human MSI-H / dMMR tumors (Efremova M et al., Nat Commun. , 2018; 9(1): 32).

[0449] MC-38 cells (purchased from Shanghai Ruilu Biotech Co., Ltd.) were collected, adjusted to a density of 5 million cells / mL, and subcutaneously implanted into PD-1 transgenic mice (purchased from Shanghai Model Organisms Center, Inc.) in the right flank at a volume of 200 μL / mouse. Twelve mice were implanted, each containing 1 x 10⁶ cells. 6 It contained cells. The tumor volume was approximately 60-150 mm² 3 When it reached, the mouse tumor volume (approximately 94 mm²) 3Based on possessing a similar average volume, each group was divided into two groups containing 6 mice: a model group and a BiAb004(hG1TM) / lenvatinib treatment group. The grouping day was set as D0. Six doses of the antibody were administered intraperitoneally to D0, D4, D7, D10, D13, and D17, respectively; lenvatinib was administered daily orally for 20 days. Tumor volume was measured by a vernier caliper. Tumor dimensions were measured twice per week using a vernier caliper after grouping, and tumor volume was calculated using the formula TV = 0.5 x ab 2 It was calculated according to (where a is the longest diameter of the tumor, b is the shortest diameter of the tumor, and TV is the volume of the tumor). The specific protocol is shown in Table 8.

[0450]

[0451] In this experiment, the sequence of the isotype control, namely human anti-HEL lysozyme IgG (anti-HEL antibody, or human IgG, abbreviated as hIgG), was from the literature (Acierno et al., title "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibody" (Acierno et al., J Mol Biol. It is derived from the variable part sequence of the Fab F10.6.6 sequence in the study reported by , 2007; 374(1): 130-46).

[0452] The results of this experiment are shown in Fig. 17.

[0453] The above results indicated that BiAb004(hG1TM) together with lenvatinib significantly inhibited the growth of MC38 tumors; and BiAb004(hG1TM) together with lenvatinib demonstrated significant efficacy against rectal and / or colon cancer of the MSI-H / dMMR phenotype.

[0454] Experimental Example 10: Pharmacodynamic Evaluation of BiAb004(hG1TM) in a C57BL / 6-hPD1 / hPDL1 / hCD73 Mouse Colon Cancer MC38-hPDL1 / hCD73 Subcutaneous Tumor Model

[0455] Female C57BL / 6-hPD1 / hPDL1 / hCD73 mice (purchased from Nanjing GemPharmatech Co., Ltd.) were divided into 8 groups, and colon cancer MC38-hPDL1 / hCD73 cells (purchased from Nanjing GemPharmatech Co., Ltd.) (2 x 10⁶) were placed on the left forelimb. 6 Cells (100 μL / mouse) were transplanted subcutaneously. The day of transplantation was designated as D0. The dosage volume was adjusted according to body weight: 10 μL / g mouse body weight (g). Isotype control antibodies (preparation and source were the same as in Experimental Example 9) or BiAb004 (hG1TM) were administered intraperitoneally twice weekly for 3 weeks at a total of 6 doses. Tumors were measured serially in this experiment, and their volume was calculated as tumor volume (mm²). 3 ) = (Tumor length x (Tumor width) 2 It was calculated by ) / 2.

[0456] The results are shown in Fig. 18 and Table 9 below.

[0457]

[0458] The above results indicated that the increase in tumor volume in the BiAb004(hG1TM) group was inhibited compared to the isotype control antibody, which suggests that BiAb004(hG1TM) significantly inhibits the proliferation of mouse MC38 cells and can effectively treat colon and / or rectal cancer.

[0459] Experimental Example 11: Study of Antibody-Mediated Phagocytic Activity of BiAb004(hG1WT) and BiAb004(hG1TM) on CHO-K1-PD1

[0460] Zhang et al. (Zhang T et al, Cancer Immunol Immunother. , 2018; 67(7):1079-1090.) and Dahan et al. (Dahan R et al., Cancer cell(2015, 28(3):285-95.) reported that the binding of Fc fragments of antibodies targeting immune checkpoints such as PD-1 and CTLA-4 to Fc receptors has a negative effect on antibody-mediated anticancer activity due to immune cell damage induced by Fc-dependent effector function, where antibody-dependent phagocytosis (ADCP) is an important mechanism causing immune cell damage.

[0461] To test the ADCP activity of BiAb004(hG1TM), murine macrophages were used as effector cells, and cell lines overexpressing the corresponding antigen were used as target cells. ADCP activity mediated by said cells was tested. Femoral bone marrow from C57BL / 6 mice (purchased from Guangdong Medical Laboratory Animal Center) was first aseptically collected and lysed in erythrocyte lysis buffer on ice for 5 minutes. Lysis was terminated by DMEM complete medium (containing 10% FBS), the lysate was centrifuged at 1000 rpm, and washed twice. The cell pellet was resuspended in 10 mL of DMEM complete medium, and macrophage colony-stimulating factor (M-CSF) was added at an active concentration of 100 ng / mL. Cells were cultured for 7 days at 37°C and 5% CO2 in a cell culture chamber. Half of the medium was exchanged, and M-CSF was added on days 3 and 5. Cell induction was completed on day 7. Cells were cleaved with 0.25% trypsin. Macrophages were collected and centrifuged at 170 xg for 5 minutes. The supernatant was discarded, and the cells were suspended in complete DMEM medium and counted. The cells were adjusted to a suitable density and packed into sterile EP tubes for further use.

[0462] CHO-K1-CTLA4-PD1 cells in the logarithmic growth phase (a cell line based on CHO-K1 cells overexpressing both human CTLA4 and PD1 antigens, constructed by Akeso Biopharma, Inc.) were collected, centrifuged at 170 xg for 5 minutes, washed with PBS, resuspended, counted, and viability determined. Carboxyfluorescein diacetate succinimidyl ester (CFSE) was diluted to 2.5 μM in PBS to resuspend the cells (staining density: 10 million cells / mL). Cells were cultured in a cell incubator for 20 minutes. 6 mL of complete DMEM medium was added to terminate the staining. Cells were centrifuged at 170 xg for 5 minutes, and the supernatant was discarded. 1 mL of complete DMEM medium was added for resuspension. Cells were cultured in an incubator for 10 minutes and adjusted to the experimental density. Cells were encoded as CHO-K1-PD1-CTLA4-CFSE. The test antibody was diluted in DMEM complete medium. The isotype control antibody, anti-HEL antibody, and medium were used as the isotype control and blank control. According to the study design, the diluted antibody and CHO-K1-PD1-CTLA4-CFSE cells were added to 1.5 mL EP tubes containing macrophages (final volume was 100 μL, effector-to-target ratio was 50,000:150,000, and antibody activity concentrations were 50, 5, and 0.5 nM). The mixture was resuspended, homogeneously mixed, and incubated in an incubator at 37°C for 2 h. 800 μL of PBS containing 1% bovine serum albumin (BSA) was added to each tube at room temperature. The mixture was centrifuged at 1200 xg for 5 minutes, and the supernatant was discarded. Cells were washed once with 800 μL of 1% PBSA. APC anti-mouse / human CD11b antibody (Biolegend, catalog number.: 101212) was diluted 400-fold with 1% PBSA and added to the corresponding samples at a rate of 100 μL / sample. The mixture was thoroughly mixed, incubated on ice for 30 minutes, washed once with 800 μL of 1% PBSA, centrifuged at 1200 xg for 5 minutes, and the supernatant was discarded. 200 μL of 1% PBSA was added to each tube to resuspend the cells. The cells were transferred to loading tubes and analyzed by a BD FACSCalibur flow cytometer. Macrophages in the system were APC. + The macrophages involved in phagocytosis were positive and double-positive for APC and CFSE. Phagocytosis rate was determined as the ratio of the number of double-positive cells to the number of APC-positive cells, and antibody-mediated ADCP activity was evaluated.

[0463] ADCP activity for each group, expressed in P%, was calculated as follows:

[0464]

[0465] The result is shown in Fig. 19.

[0466] The above results showed that in an antibody validation system for mediating phagocytic activity, the phagocytic activity of CHO-K1-PD1-CTLA4 cells mediated by macrophages mediated by BiAb004(hG1TM) did not show a significant difference compared to the phagocytic activity of the isotype control antibody anti-HEL antibody when compared to BiAb004(hG1WT), indicating that BiAb004(hG1TM) did not possess ADCP activity.

[0467] The above results suggest that amino acid mutations introduced by BiAb004(hG1TM) can effectively eliminate ADCP activity, and remarkable technical effects are obtained.

[0468] Experimental Example 12: Significantly Enhanced Immune Response of Immune Cells Against Human Gastric Cancer KATO III Cells by BiAb004(hG1TM)

[0469] PBMC is Ficoll-PaqueTM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Raji-PDL1 and KATO III cells (purchased from the Chinese Academy of Sciences Shanghai Cell Bank) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raji-PDL1 cells were treated with 2 μg / mL Mitomycin C (MMC) for 1 h. SEB-activated PBMCs and MMC-treated Raji-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Raji-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells were seeded into 96-well plates at cell / well. KATO III cells in the logarithmic growth phase were collected, and 5 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0470] The result is shown in Fig. 20.

[0471] The above results indicated that BiAb004(hG1TM) more significantly enhanced the immune response of immune cells against human gastric cancer cells KATO III, characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1WT), and thus BiAb004(hG1TM) is promising for treating gastric cancer.

[0472] Experimental Example 13: Significantly Enhanced Immune Response of Immune Cells Against Human Cervical Cancer Hera Cells by BiAb004(hG1TM)

[0473] PBMC is Ficoll-Paque TM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 and Hera cells (purchased from the Chinese Academy of Sciences Cell Bank) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. Hera cells in the logarithmic growth phase were collected, and 5 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0474] The results are shown in Fig. 21.

[0475] The above results indicated that BiAb004(hG1TM) more significantly enhanced the immune response of immune cells against human cervical cancer Hera cells, characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1WT); therefore, BiAb004(hG1TM) is promising for the treatment of cervical cancer.

[0476] Experimental Example 14: Significantly Enhanced Immune Response of Immune Cells Against Human T-Cell Lymphoma Jurkhat Cells by BiAb004(hG1TM)

[0477] PBMC is Ficoll-PaqueTM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Raj-PDL1 and human T-cell lymphoma Jurkat cells (purchased from the Chinese Academy of Sciences Cell Bank) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raj-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Raj-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Raj-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. Jurkat cells in the logarithmic growth phase were collected, and 1 x 10⁶ 5 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0478] The results are shown in Fig. 22.

[0479] BiAb004(hG1TM) more significantly enhanced the immune response of immune cells against human T-cell lymphoma Jurkhat cells, characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1WT), while eliminating ADCC and CDC (i.e., ADCP) effects; said antibody possesses equivalent or higher pharmacological activity at doses of 1.34 nM and 20 nM compared to BiAb004(hG1WT), and is promising for treating T-cell lymphoma.

[0480] Experimental Example 15: Significantly Enhanced Immune Response of Immune Cells Against Human Nasopharyngeal Carcinoma CNE-2Z Cells by BiAb004(hG1TM)

[0481] PBMC is Ficoll-Paque TM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 and CNE-2Z cells (purchased from GuangZhou Jennio Biotech Co., Ltd.) were cultured in DMEM + 10% FBS complete medium. The PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. CNE-2Z cells in the logarithmic growth phase were collected, and 3 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0482] The results are shown in Fig. 23.

[0483] The above results indicated that BiAb004(hG1TM) more significantly enhanced the immune response of immune cells against human nasopharyngeal carcinoma cells CNE-2Z, characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1WT), based on the effective elimination of ADCC, CDC, and ADCP effects, and that BiAb004(hG1TM) possessed particularly significant superiority at 20 nM.

[0484] The above results indicated that BiAb004(hG1TM) possessed better or equivalent pharmacological activity compared to BiAb004(hG1WT) based on effectively eliminating ADCC, CDC, and ADCP activities.

[0485] Experimental Example 16: Significantly Enhanced Immune Response of Immune Cells Against Human Breast Cancer MDA-MB-231 Cells by BiAb004(hG1TM)

[0486] PBMC is Ficoll-Paque TM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 and MDA-MB-231 cells (purchased from GuangZhou Jennio Biotech Co., Ltd.) were cultured in DMEM + 10% FBS complete medium. The PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. CNE-2Z cells in the logarithmic growth phase were collected, and 3 x 10⁶ 4Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0487] The results are shown in Fig. 24.

[0488] BiAb004(hG1TM) equally or more significantly enhanced the immune response of immune cells against human breast cancer MDA-MB-231 cells characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1WT).

[0489] The above results indicated that BiAb004(hG1TM) possesses better or equivalent pharmacological activity compared to BiAb004(hG1WT) based on effectively eliminating ADCC, CDC, and ADCP effects, which indicates potential for the treatment of human breast cancer.

[0490] Experimental Example 17: Significantly Enhanced Immune Response of Immune Cells Against Human Mesothelioma NCI-H2452 Cells by BiAb004(hG1TM)

[0491] PBMC is Ficoll-Paque TMPBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Raj-PDL1 and NCI-H2452 cells (purchased from the Chinese Academy of Sciences Shanghai Cell Bank) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raj-PDL1 cells were treated with 2 μg / mL MMC for 1 h. SEB-activated PBMCs and MMC-treated Raj-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Raj-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. CNE-2Z cells in the logarithmic growth phase were collected, and 3 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0492] The result is shown in Fig. 25.

[0493] The above results indicated that BiAb004(hG1TM) more significantly enhanced the immune response of immune cells against human mesothelioma cells NCI-H2452, characterized by significantly increased secretion levels of IL-2, compared to BiAb004(hG1WT); therefore, BiAb004(hG1TM) is promising for the treatment of mesothelioma.

[0494] Experimental Example 18: Significantly enhanced immune response of immune cells against human non-small cell lung cancer (human lung adenocarcinoma) by BiAb004(hG1TM) in combination with anlotinib

[0495] PBMC is Ficoll-Paque TMPBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 cells were cultured in RPMI 1640 + 10% FBS complete medium, and A549 cells were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells were seeded into 96-well plates at cell / well. Logarithmic growth phase A549 cells (purchased from the Chinese Academy of Sciences Cell Bank) were collected, and 5 x 10 4 Cells were seeded into 96-well plates. Diluted antibodies were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in all experiments was 10% FBS + RPMI 1640.

[0496] As shown in Fig. 26, BiAb004(hG1TM) with anlotinib hydrochloride more significantly enhanced the immune response of immune cells against human non-small cell lung cancer (human lung adenocarcinoma) A549 cells, characterized by significantly increased secretion levels of IL-2, compared to BiAb004(hG1TM) monotherapy, BiAb004(hG1WT) monotherapy, and BiAb004(hG1WT) with anlotinib hydrochloride; therefore, BiAb004(hG1TM) with anlotinib hydrochloride is promising for treating human non-small cell lung cancer or human lung adenocarcinoma.

[0497] Experimental Example 19: Significantly Enhanced Immune Response of Immune Cells Against Human Small Cell Lung Cancer NCI-H446 Cells by BiAb004(hG1TM) in Conjunction with Anlotinib

[0498] PBMC is Ficoll-Paque TM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Raj-PDL1 and NCI-H446 cells (purchased from the Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raj-PDL1 cells were treated with 2 μg / mL MMC for 1 h. SEB-activated PBMCs and MMC-treated Raj-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Raj-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells were seeded into 96-well plates at cell / well. NCI-H446 cells in the logarithmic growth phase (purchased from the Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences) were collected, and 8 x 10⁶ 4Cells were seeded into 96-well plates. Diluted antibodies and anlotinib were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in this experiment was 10% FBS + RPMI 1640.

[0499] The results are shown in Fig. 27.

[0500] BiAb004(hG1TM) with anlotinib hydrochloride more significantly enhanced the immune response of immune cells against human small cell lung cancer NCI-H446 cells characterized by significantly increased secretion levels of IL-2 compared to BiAb004(hG1TM) monotherapy, BiAb004(hG1WT) monotherapy, and BiAb004(hG1WT) with anlotinib hydrochloride, and thus BiAb004(hG1TM) with anlotinib hydrochloride is promising for treating human small cell lung cancer.

[0501] Experimental Example 20: Significantly enhanced immune response of immune cells against human squamous cell lung cancer NCI-H226 cells by BiAb004(hG1TM) in combination with anlotinib

[0502] PBMC is Ficoll-Paque TMPBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Raj-PDL1 and NCI-H226 cells (purchased from the Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Raj-PDL1 cells were treated with 2 μg / mL MMC for 1 h. SEB-activated PBMCs and MMC-treated Raj-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Raj-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells were seeded into 96-well plates at cell / well. NCI-H226 cells in the logarithmic growth phase were collected, and 5 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies and anlotinib were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in this experiment was 10% FBS + RPMI 1640.

[0503] The results are shown in Fig. 28.

[0504] BiAb004(hG1TM) monotherapy more significantly enhanced the immune response of immune cells against human squamous cell lung cancer NCI-H226 cells, characterized by significantly increased secretion levels of IL-2, compared to BiAb004(hG1WT) monotherapy.

[0505] BiAb004(hG1TM) with anlotinib hydrochloride significantly enhanced the immune response of immune cells against human squamous cell lung cancer NCI-H226 cells compared to BiAb004(hG1TM) monotherapy and BiAb004(hG1WT) monotherapy, and demonstrated comparable pharmacological activity using BiAb004(hG1TM) with anlotinib.

[0506] The above results indicated that BiAb004(hG1TM) possessed better or equivalent pharmacological activity compared to BiAb004(hG1WT) monotherapy or BiAb004(hG1WT) in combination with anlotinib, based on the effective elimination of ADCC, CDC, and ADCP effects, which indicates better efficacy for treating human squamous cell lung cancer.

[0507] Experimental Example 21: Significantly Enhanced Immune Response of Immune Cells Against Human Colorectal Cancer SW48 Cells with MSI-H / dMMR Phenotype by BiAb004(hG1TM)

[0508] SW48 is a human colorectal cancer cell line and is identified with the MSI-H / dMMR phenotype (Branch P et al., (1995), Cancer Res , 55(11): 2304-2309.). This was used to detect enhanced immune cell responses to tumors with the MSI-H / dMMR phenotype by BiAb004(hG1TM).

[0509] In this experiment, PBMC is Ficoll-Paque TMPBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 cells were cultured in RPMI 1640 + 10% FBS complete medium, and SW48 cells (purchased from GuangZhou Jennio Biotech Co., Ltd.) were cultured in DMEM + 10% FBS complete medium. PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5 Cells / well were seeded into 96-well plates. SW48 cells in the logarithmic growth phase were collected, and 2 x 10⁶ 5 Cells were seeded into 96-well plates. Diluted antibodies and anlotinib were added according to the study design. The mixture was homogeneously mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions. The medium used in this experiment was 10% FBS + RPMI 1640.

[0510] The result is shown in Fig. 29.

[0511] BiAb004(hG1WT) and BiAb004(hG1TM) both significantly enhanced the immune response of immune cells against human colorectal cancer SE48 cells of the MSI-H / dMMR phenotype, characterized by significantly increased secretion levels of IL-2 compared to anti-HEL antibodies.

[0512] The above results indicated that BiAb004(hG1TM) possessed better or equivalent pharmacological activity compared to BiAb004(hG1WT) based on effectively eliminating ADCC, CDC, and ADCP effects, which indicates potential for treating solid tumors of the MSI-H / dMMR phenotype, particularly colorectal and / or rectal cancer of the MSI-H / dMMR phenotype.

[0513] Experimental Example 22: Significantly Enhanced Immune Response of Immune Cells Against Human Colorectal Cancer SW837 Cells with MSI-H / dMMR Phenotype by BiAb004(hG1TM)

[0514] SW387 is a human colorectal cancer cell line with a non-MSI-H / dMMR (i.e., MSS) phenotype (Guo J et al., Cancer Res. , 2011;71(8):2978-2987.), in this example, BiAb004(hG1TM) was used to detect an enhanced immune cell response to tumors of the non-MSI-H / dMMR phenotype.

[0515] PBMC is Ficoll-Paque TM PBMCs were isolated from healthy human peripheral blood according to the Plus reagent instructions, and the isolated PBMCs were counted and frozen. Large-PDL1 cells were cultured in RPMI 1640 + 10% FBS complete medium, and SW837 cells (purchased from Shanghai Honsun Biological Technology Co., Ltd.) were cultured in 10% FBS + Leibovitz L-15 complete medium (purchased from Gibco). PBMCs were thawed and activated with 0.5 μg / mL SEB for 2 days. On the day of the experiment, Large-PDL1 cells were treated with 2 μg / mL MMC for 1 hour. SEB-activated PBMCs and MMC-treated Large-PDL1 cells were collected, washed twice with PBS, resuspended in RPMI 1640 + 10% FBS complete medium, and counted. Large-PDL1 and PBMC cells were 1 x 10⁶ 5Cells were seeded into 96-well plates at cell / well. SW48 cells in the logarithmic growth phase were collected, and 5 x 10⁶ 4 Cells were seeded into 96-well plates. Diluted antibodies and anlotinib were added according to the study design. The mixture was uniformly mixed and incubated for 3 days in a 5% CO2 incubator at 37°C. After 3 days, the cell culture supernatant was collected and tested for IL-2 according to the ELISA KIT instructions.

[0516] The media used in this experiment were all 10% FBS + RPMI 1640.

[0517] The result is shown in Fig. 30.

[0518] Both BiAb004(hG1WT) and BiAb004(hG1TM) significantly enhanced the immune response of immune cells against human colorectal cancer SW837 cells with a non-MSI-H / dMMR phenotype compared to anti-HEL antibodies. In the high-dose group, the pharmacological activity of BiAb004(hG1TM) was superior to that of BiAb004(hG1WT), characterized by significantly increased secretion levels of IL-2.

[0519] The above results indicated that BiAb004(hG1TM) possessed better or equivalent pharmacological activity compared to BiAb004(hG1WT) based on effectively eliminating ADCC, CDC, and ADCP effects, which indicates potential for treating solid tumors of the non-MSI-H / dMMR phenotype, particularly colon cancer and / or rectal cancer of the non-MSI-H / dMMR phenotype.

[0520] Although specific embodiments of the present invention have been described in detail, those skilled in the art will understand. Various modifications and substitutions may be made in greater detail in accordance with all the teachings disclosed, and all such modifications are within the scope of protection of the present invention. The full scope of the present invention is provided by the appended claims and any equivalents thereof.

Claims

Claim 1 A bispecific antibody comprising a first protein-active region targeting PD-1 and a second protein-active region targeting CTLA4; the first protein-active region is an immunoglobulin and the second protein-active region is a single-chain antibody; the amino acid sequence of the heavy chain of the immunoglobulin is described in SEQ No. 40 and the amino acid sequence of the light chain of the immunoglobulin is described in SEQ No. 24; the amino acid sequence of the heavy chain variable portion of the single-chain antibody is described in SEQ No. 43 and the amino acid sequence of the light chain variable portion of the single-chain antibody is described in SEQ No. 44; the single-chain antibody is linked to the C-terminus of the heavy chain of the immunoglobulin; the first protein-active region is linked to the second protein-active region by a first linker fragment; the heavy chain variable portion of the single-chain antibody is linked to the light chain variable portion of the single-chain antibody by a second linker fragment; and the first linker fragment and the second linker fragment are the same or different. Claim 2 A bispecific antibody according to claim 1, wherein the amino acid sequences of the first linker fragment and the second linker fragment are independently selected from SEQ ID NO. 25 and SEQ ID NO.

26. Claim 3 A bispecific antibody according to claim 1, wherein the amino acid sequences of the first linker fragment and the second linker fragment are those described in SEQ ID NO.

26. Claim 4 Isolated nucleic acid molecule encoding a bispecific antibody according to claim 1. Claim 5 A vector comprising an isolated nucleic acid molecule according to paragraph 4. Claim 6 A host cell containing isolated nucleic acid molecules according to paragraph 4. Claim 7 A conjugate comprising a bispecific antibody and a conjugated moiety, wherein the bispecific antibody is a bispecific antibody according to claim 1, and the conjugated moiety is a detectable label comprising a radioisotope, a fluorescent substance, a luminescent substance, a coloring substance, or an enzyme. Claim 8 A kit for treating a tumor or anemia comprising a bispecific antibody according to claim 1, wherein the kit further comprises a second antibody capable of specifically recognizing the bispecific antibody or conjugate. Claim 9 A kit according to claim 8, wherein the second antibody further comprises a detectable label including a radioactive isotope, a fluorescent substance, a luminescent substance, a coloring substance, or an enzyme. Claim 10 A pharmaceutical composition for treating a tumor or anemia comprising a bispecific antibody according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient. Claim 11 A pharmaceutical composition according to claim 10, further comprising one or more anti-tumor chemotherapy agents. Claim 12 In claim 11, the anti-tumor chemotherapy agent is a tyrosine kinase inhibitor; and the tyrosine kinase inhibitor is a pharmaceutical composition in which anlotinib or a pharmaceutically acceptable salt thereof, or lenvatinib or a pharmaceutically acceptable salt thereof. Claim 13 A pharmaceutical composition according to claim 10, wherein the unit dosage of the pharmaceutical composition is 100-1000 mg, 200-800 mg, 200-500 mg, 300-600 mg, 400-500 mg, or 450 mg based on the mass of the bispecific antibody. Claim 14 A combination product for treating a tumor or anemia, comprising a first product and a second product in separate packages, wherein the first product comprises a bispecific antibody according to claim 1; and the second product comprises one or more anti-tumor chemotherapy agents. Claim 15 In paragraph 14, the anti-tumor chemotherapy agent is a tyrosine kinase inhibitor; and the tyrosine kinase inhibitor is a combination product in which anlotinib or a pharmaceutically acceptable salt thereof, or lenvatinib or a pharmaceutically acceptable salt thereof. Claim 16 In paragraph 14, the first product and the second product are combination products that independently further comprise one or more pharmaceutically acceptable excipients. Claim 17 A combination product that additionally includes a package insert in Clause 14. Claim 18 A combination product according to claim 14, wherein the unit dose of the first product is 100-1000 mg, 200-800 mg, 200-500 mg, 300-600 mg, 400-500 mg, or 450 mg based on the mass of the bispecific antibody. Claim 19 A combination product according to claim 14, wherein the unit dose of the second product is 0.1-100 mg, 0.5-50 mg, 1-20 mg, 2-15 mg, 4-12 mg, or 8-12 mg based on the mass of the anti-tumor chemotherapy agent. Claim 20 A pharmaceutical composition according to claim 10, wherein the tumor is selected from one or more of melanoma, kidney cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, stomach cancer, liver cancer, lung cancer, ovarian cancer, leukemia, breast cancer, mesothelioma, cervical cancer, endometrial cancer, lymphoma, and nasopharyngeal cancer. Claim 21 In paragraph 20, the lung cancer is a pharmaceutical composition selected from one or more of non-small cell lung cancer, small cell lung cancer, and squamous cell lung cancer. Claim 22 A pharmaceutical composition in which, in paragraph 20, the gastric cancer is gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. Claim 23 A pharmaceutical composition in which, in claim 10, the tumor is a solid tumor of the MSI-H / dMMR phenotype. Claim 24 A pharmaceutical composition according to claim 23, wherein the solid tumor of the MSI-H / dMMR phenotype is selected from one or more of colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm. Claim 25 In Clause 14, the tumor is a combination product selected from one or more of melanoma, kidney cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, stomach cancer, liver cancer, lung cancer, ovarian cancer, leukemia, breast cancer, mesothelioma, cervical cancer, endometrial cancer, lymphoma, and nasopharyngeal cancer. Claim 26 In paragraph 25, the lung cancer is a combination product selected from one or more of non-small cell lung cancer, small cell lung cancer, and squamous cell lung cancer. Claim 27 In Clause 25, the combination product is gastric cancer, which is gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. Claim 28 In Clause 14, the combination product is a solid tumor of the MSI-H / dMMR phenotype. Claim 29 A combination product according to claim 28, wherein the tumor of the MSI-H / dMMR phenotype is selected from one or more of colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma, and ovarian germ cell neoplasm. Claim 30 A pharmaceutical composition according to claim 10, wherein the administration of the pharmaceutical composition is performed before or after surgical treatment or before or after radiation therapy. Claim 31 A pharmaceutical composition according to claim 10, wherein the unit dose of the bispecific antibody is 0.1-100 mg per kg of body weight, and the dose is provided once every 3, 4, 5, 6, 10 days, 1 week, 2 weeks, or 3 weeks; and the route of administration is intravenous drip infusion or intravenous injection. Claim 32 A pharmaceutical composition according to claim 10, wherein the administration of the bispecific antibody is performed in cycles of 2 or 3 weeks, and the bispecific antibody is administered intravenously on the first day of each cycle. Claim 33 delete Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete Claim 41 delete Claim 42 delete Claim 43 delete Claim 44 delete Claim 45 delete

Citation Information

Patent Citations

  • Antibodies and conjugates thereof

    KR1020180104635A

  • Anti-CTLA4 and anti-PD-1 bifunctional antibodies, pharmaceutical compositions thereof, and uses thereof

    KR1020190052677A